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Recent technological advances allow for high throughput profiling of biological 
systems in a cost-efficient manner. The low cost of data generation is leading us to the 
“big data” era within the broader field of biomedicine. The availability of biology-based 
big data provides unprecedented opportunities but also raises new challenges for data 
mining and analysis. Machine learning algorithms have demonstrated their power of 
increasing efficiency and accuracy in bioinformatics analysis and recent efforts using 
machine learning to analyze biological data have benefited the computational biology 
community. Although progress is being made to date there are still many algorithms and 
heuristics that are not being shared in their entirety to scientific community. This 
dissertation helps to reverse this by presenting a truly open source platform to perform 
un-supervised genomic clustering and supervised clustering of cancer patient drug 
response.  
I started by explore the classic clustering algorithms and applying these 
algorithms to molecular surveillance and also studying infectious disease dynamics. 
Traditionally, computational methods for this type of analysis are based on gapped 
alignments to a reference followed by the construction of a phylogenetic tree. In 
molecular epidemiology, transmission clusters are usually inferred by identifying 
grouped samples within a phylogenetic tree that can help delineate which viruses were 
likely transmitted from person to person (i.e. contact tracing). In the past decade, great 




number of highly successful applications, current phylogeny-based methods face a 
number of challenges. Phylodynamic tools and algorithms include highly 
computationally intensive stages, such as multiple sequence alignments and Bayesian 
Markov Chain Monte Carlo tree inferences, which often make them unable to scale to 
arbitrarily large data sets of samples. Phylogeny-based approaches in molecular 
epidemiology have room for improvement in allowing reliable inference of transmission 
history within transmission clusters, which is a crucial step in studying recent and 
emerging outbreaks. In Chapter III we outline our Boolean logic-based lightweight 
clustering algorithm that outcompetes existing heuristics in analyzing viral outbreaks and 
we hope that our platform will be utilized by public health officials in studying viral 
disease dynamics and guiding public health interventions. 
After achieving successful clustering of microbial genomic data (as seen above), I 
moved on to utilize supervised clustering algorithms to analyze microarray and RNA-seq 
data for human cancer patients. Precision medicine for oncology is rapidly growing and 
evolving, and machine learning will very likely play a key role within clinical oncology 
moving forward. A key goal of precision medicine for cancer/oncology is the accurate 
prediction of optimal drug therapies based on individualized molecular profiles of patient 
tumors. For this project we gathered raw gene expression data from cell lines that had 
already been tested against a diverse set of small molecule libraries by the National 
Cancer Institute (NCI-60). I started to build drug specific machine learning models using 
this microarray data with accompanying drug response data (in the form of growth 




algorithms on cancer cell lines including those from the recent NCI-DREAM Challenge. 
The highly accurate prediction results on cell lines encouraged me to apply this model to 
ovarian cancer patients from Northside Hospital (Atlanta, GA) and gathered by Dr. John 
McDonald’s lab at Georgia Tech and several Gene Expression Omnibus (GEO) data sets 
from the National Center for Biotechnology Information (NCBI). Chapter IV discusses  
the details of this work which has now been published in PLOS ONE. I then continued to 
expand the program to analyze RNA-seq data and employed matched sets of RNA-seq 
data and drug-response profiles from The Cancer Genome Atlas (TCGA) database. By 
clustering patients into two groups (i.e. responders versus non-responders), we were able 
to predict optimal drug therapies for the individual patients. Chapter V discusses details 





CHAPTER 1. INTRODUCTION 
With the advent of the era of microarray technology followed by next generation 
sequencing (NGS) platforms there is great promise that these technologies can 
revolutionize our approach to disease prevention, and cancer detection and treatment [1-
3]. In 2005, we witnessed the beginning of the NGS era with platforms from companies 
such as ABI (SOLID), Roche (454) and Illumina (Genome Analyzer)[4]. These 
technologies have developed rapidly since this time and the cost of sequencing (per 
million reads) continues to decrease to present day. As data accumulates in public 
repositories we face the need to optimize algorithms to be able to scale well with the 
exponential increase in data [5]. Our solution is to utilize k-mer based alignment-free 
algorithms and heuristics that do not require canonical string matching/hamming distance 
calculations. k-mers typically refer to substrings of length k extract from a string. In 
sequencing analysis, k-mer refers to substrings of length k abstract from a string. Here, 
we used a sliding-window approach to obtain all k-mers and their frequencies. 
Microarray probes are composed of k-mers that are short sections of genes or other DNA 
elements, that are used to measure the expression level of large numbers of genes 
simultaneously or to genotype large numbers of genetic variants within a genome. 
Affymetrix microarray gene chips use k-mer probes of 25-mer oligos and output the 
expression level of those probe sets [6-9]. Our approach utilizes two main approaches: a) 
k-mer based un-supervised machine learning (ML) clustering algorithm that computes 




matrices of microarray probe data. The latter supervised ML cluster algorithm was 
specifically trained to predict optimal drug therapy for cancer patients. In the summary 
section above we mention how recent efforts using ML for precision medicine have 
benefited from community assessments of predicted drug response [10, 11]. Our core 
principle for the work presented in this dissertation revolves around building truly open 
source platforms (Fig. 1). From this work we have built version controlled software that 
utilizes publically available training and testing data which is able to a) interrogate 100k+ 
samples, b) be applied to many different type of data, c) optimize normalization to limit 
batch effects, d) reduce over fitting and eliminate substitution bias [12, 13] and finally e) 
accurately predict the ground truth state. By providing true open access to our software, 
we hope to encourage additional improvements to our methods with constructive 
comparisons with alternative approaches leading to the development of optimal strategies 





Figure 1 – Open source platform, which provides both Data Structure and Data 
Analysis. 
1.1 Genomic Clustering 
Genomic clustering is an important problem in bioinformatics [14, 15]. Significant 
progress with DNA-string matching algorithms continues. Among the well-known 
techniques of DNA-string matching are the Smith-Waterman algorithm [16] for local 
























Markov’s model for multiple sequence alignment [18]. Although their contributions have 
been crucial to modern computational biology they do have their limitations. These 
methods all depend on a gap penalty alignment to a given reference and are also 
computationally intensive. Standard alignment and matching algorithms are known to be 
processor intensive even for the comparison of moderate length DNA sequences. Rapid 
advances in automated DNA sequencing technology has created a need for statistical 
summarization of large volumes of sequence data with the end goal of efficient and 
effective statistical analysis. There is a shortage of rapid and parsimonious procedures 
algorithms in this space. In Chapter II, we present our solution to this problem with 
utilizing an open source software package that utilizes an elegant and efficient alignment 
free k-mer approach [19].  By avoiding alignment, we can directly apply clustering 
algorithms on the numerical matrices derived from the DNA sequences. These clustering 
results are discussed in Chapter III. This approach presents an open source platform for 
genomic clustering based on a novel calculation for the pairwise distances between 
genomes. 
1.2 Boolean analysis 
Boolean analysis has been widely used in data mining and popularized by Flament 
(1976) [20]. By utilizing Boolean logical formulae, this approach can detect deterministic 
dependencies between the matrices of data that share homology. Some basic operations 
are conjunction x˄y (AND), disjunction x˅y (OR), negation ¬x (NOT), and exclusive-
OR xÅy (XOR). We term our approach Boolean when we formulate matrices of data into 




represent true (T) and 0 is taken to represent false (F). In Chapter II, we have defined the 
pairwise distance of two genomic sequences based on the exclusive-OR operation. Each 
sequence is fragmented into small k-mers, and the presence of a k-mer is considered as 1, 
the absence as 0. The Boolean analysis of two sequences then becomes an algebraic 
function of these two binary values as mentioned above.  
1.3 Machine learning on bioinformatics  
Machine learning is the development of algorithms and techniques that allow a 
computer to learn. It has a broad spectrum of applications such as stock market analysis, 
cheminformatics, and bioinformatics to name a few. Recently, the amount of biological 
data requiring analysis has exploded, and many studies have been using machine learning 
methods to analyze this data [21, 22]. Hence, machine learning in bioinformatics has 
become an important research area for both computer scientists and biologists. It requires 
the development of tools and methods capable of transforming all of this heterogeneous 
data into biological knowledge about the underlying mechanism. These tools and 
techniques should allow us to go beyond a mere description of the data and provide 
knowledge in the form of testable models. With this work we will be able to create 
simplified abstractions that constitute a model heuristic and from this we will be able to 
obtain predictions from this system. There are several biological domains where machine 
learning techniques are applied for knowledge extraction from data.  
In a modeling problem, the ‘learning’ term refers to running a computer program to 




theory when building computational models since the objective is to make inferences 
from a sample. The two main steps in this process are to induce the model by processing 
huge amounts of data and to represent the model and make inferences efficiently. It must 
be noted that the efficiency of the learning and inference algorithms, as well as their 
space and time complexity, transparency and interpretability, can be as important as their 
predictive accuracy. The process of transforming data into knowledge is both iterative 
and interactive. The iterative phase consists of several steps. In the first step, we need to 
integrate and merge the different sources of information into one single format. The 
detection and resolution of outliers and inconsistencies is an important first step and we 
employ various techniques to solve this including data warehouse techniques. In the 
second step, it is necessary to select, clean and transform the data. As shown in Chapter 
II, we utilize a pairwise normalization approach to ensure that the microarray data for 
each patient is on the same scale as the learning set and the other patient samples. This is 
then followed by the next step which selects relevant and non-redundant variables. This 
also can be referred to as feature selection algorithms we used in Chapter IV, and the 
most effective algorithm on our data set, recursive feature elimination (RFE). In the 
fourth step, called data mining, we take the objectives of the study into account in order 
to choose the most appropriate analysis objective for the data being analyzed. Once the 
version controlled model is obtained, it should be evaluated and interpreted both from 
statistical and biological points of view and, if necessary, we should return to previous 
steps for a new iteration to improve the model and then increment the version control 




domain. We discuss the optimization of our program in Chapter VI. Optimization 
problems can be regarded as the task of finding an optimal solution in the space of many 
possible solutions. The choice of the optimization method is crucial for the solution of the 
problem. Optimization approaches to biological problems can be classified into exact and 
approximate methods. Exact methods output the optimal solutions when convergence is 
achieved. However, they do not necessarily converge in every instance. Approximate 
algorithms always output a candidate solution, but it is not guaranteed to be the optimal 
one. Optimization is also a fundamental task when modeling from data. In fact, the 
process of learning from data can be regarded as searching for the model that gives the 
data the best fitting. In this search, in the space of all possible models, any type of 
heuristic can be used. Therefore, optimization methods can also be an ingredient in 
modeling. 
Bioinformatics is the development and application of computational methods for 
management, analysis, interpretation, and prediction, as well as for the design of 
experiments. The goal in machine learning is to extract useful information from a body of 
data by building good probabilistic models and to automate the process as much as 
possible. 
1.4 Precision medicine in cancer treatment 
Precision medicine is an approach to patient care that allows doctors to select 
treatments that are most likely to help patients based on a genetic understanding of their 




advances in science and technology have helped speed up the pace of this area of 
research. 
In present day when you are diagnosed with cancer you usually receive the same 
treatment as others who have the same type and stage of cancer. Even so, different people 
may respond differently and until recently doctors didn’t have a way of formally 
understanding why. After decades of research, scientists now understand that patients’ 
tumors have genetic changes that cause cancer to grow and spread and these are being 
elucidated in greater numbers and greater detail over the past decade. Researchers have 
also learned that the changes that occur in one person’s cancer may not occur in others 
who have the same type of cancer. And, the same cancer-causing changes may be found 
in different types of cancer. 
Optimal prediction of personalized cancer drug therapies using machine learning is 
an area of intense research activity in recent years and numerous community assessments 
have been carried out in pursuit of maximal sensitivity and specificity [25-28]. As 
mentioned we were frustrated at how little code was actually shared publically by this 
previous work and we sought to change that trend by creating a framework for truly open 
source, version controlled software that utilizes publically available training and testing 
data, using a highly versatile support vector machine (SVM) algorithm utilizing standard 






1.5 Chapters  
CHAPTER II outlines the methods used on k-mer generation, clustering and 
modeling. This chapter gives the definition of k-mer and dataset we used on learning and 
testing. 
CHAPTER III discuss the genomic clustering based on k-mer alignment free 
approach. This chapter shows the clustering result on several data sets, and preparing the 
clustering algorithm for modeling and predicting on CHAPTER IV 
CHAPTER IV presents a novel machine learning algorithm that predicting 
optimal cancer therapy. 
CHAPTER V discusses a novel application of the predicting model from 
CHAPTER IV. 





CHAPTER 2. MATERIALS AND METHODS 
2.1 k-mer  
2.1.1 Definition 
Nucleotides A, C, G, and T are assigned as [00, 01, 10, 11] and then we used a 
binary data structure to maintain them in memory. For example, a sequence ATTCG 
would be transferred to [00, 11, 11, 01, 10], which can be stored as a decimal number, 
246. In sparse matrix form we array these into a vector sequence based upon the 
magnitude of k-mer (Fig. 2A), and most of our analyses are based on the vector format. 
We demonstrate the conversion into matrix format of k-mer data in Figure 2B. Once the 
k-size was determined we retain the count of each k-mer.  





Figure 2 – Universal k-mer encoding.  Universal encoding defined using the 
Quaternary-Decimal encoding system. A) vector form B) matrix form. 
In our k-mer encoding, there is an equivalency between our matrix (τ) and its linear 








 Where ijf  is frequency of k-mer in the sequence. We present both format for 
different application of analysis. 
2.1.2 Investigating relationship of k-mer occupancy ( t ) and Shannon entropy to 
optimize k-mer length 
Shannon entropy is the average unpredictability in a random variable, which is 
equivalent to its information content, defined by equation number (2). 
     (2) 
Where  is the Shannon entropy of the genome sequence (s), N is the possible 
outcomes [A, C, G, T],  is the probability of occurrence of each nucleotide in that 
sequence. 
k-mer occupancy t  is the calculated as the proportion of k-mers divided by the 











      (3) 
where ( , )s kt  is the k-mer occupancy of the genome sequence (s), N is the possible 
outcomes [A, C, G, T],  is the occurrence of each possible k-mer in that sequence. 
Taking in Shannon entropy and k-mer occupancy t , we plot t divided by the log of 
1














genome size (L) on the y-axis and the H(s) to the power of 10 on the x-axis as defined 







t ,  x:      (4) 
Optimizing k-mer length for a given set of k-matrices and equivalent linear vectors 
relies on local optimal slope (m) of the overall trend line of  relationships of the 
dataset, assuming a variance of genome lengths less than 30% of the overall variance. 
 
Figure 3 – Different k-mer lengths and k-mer occupancy, genome size, and entropy 
for 2569 bacterial genomes. 
Given a linear polynomial function for these data points, we will attempt to 
maximize a within this function (i.e. slope) to allow for the optimal k size for a given data 
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= +       (5) 
Fit linear polynomial function (Equation 5) to Figure 3, we can get that k=10 give 
us the optimal slope in equation number (5). 
This relationship allows for determination of the ideal k-mer length to be utilized 
for a given subset of samples and confirms that genome encoding will be ideal by 
optimizing the slope of the equation number (5) to a maximum given a strong  
relationship of the data points with the desirable outcome of increasing size and 
complexity yield higher values, but the maximization of the slope for a set of k-mer 
lengths prevents overly sparse (Fig. 3, k=12) or overly saturated (Fig 3, k=6) matrix 
comparisons.  
2.1.3 Discrete Mathematics on t  matrices Differential Occupancy 
We then went on to carry out discrete mathematics on these compiled matrices to 
determine the extent to which we could define genome similarity using this encoding. 
One simple metric is the resultant value of the XOR Boolean operator between two 
sparse vectors, which we here define as delta tau ( ktD ), or differential occupancy, where 
k defines the k-mer length. We define the term differential occupancy as the XOR 
function between two sparse vectors that derives the resultant sparse vector followed by 
summing the number of non-zero elements then dividing by the total number of possible 












D =      (6) 
We provide all data as to the pairwise differential ktD encoding between species p 
and q specifying k-mer length. Although these pairwise ktD calculations took ~48 hours 
of computation time on a standard Intel i5 processor with 32 GB of RAM. This Boolean 
encoding system allows for hardware accelerators such as field-programmable gate array 
(FPGA) processors to quickly compare this data with specific combinations of half and 
full adder circuits. Indeed, this Georgia Tech encoding in part is envisioned in an 
ecosystem where memory and compute capabilities make it possible for such large-scale 
comparisons and allows for complete sparse matrix calculations over increasing k-mer 
size. Using this ktD we carry out hierarchical clustering and obtain expected clustering of 
these bacterial genomes. It should be noted that this analysis is not a phylogenetic 
analysis, rather analysing global genomic content, but will detect shared lineage as well 
as putative horizontal gene transfer events. 





2.2 Matrix format 
We present a matrix format to store transformed sequences, which we term k-
matrix. Each column represents one sample, and k-mer frequencies are stored in each 
row. This format benefits on data aggregation and analysis. For example, we used matrix 
format for denoising in Chapter III. We sum the appearance of each k-mer in the last 
column to carry out further processing.  
 
Where m is the number of samples, and n is equal to 4k , all possible number of k-
mers. ija is the appearance of k-mer, which can be 0 or 1. The sum of each k-mer 
appearance among m samples are saved as
isum . Then we remove k-mers (rows) which 
isum is smaller than certain threshold. In Chapter III, we dynamically calculate threshold 
based on z-score of 2.  
2.3 Affymetrix microarray 
Microarray data normalization. Patients’ gene expression microarray (.CEL) files 
are analyzed by using the Affymetrix Microarray Analysis tool, expression console 
(http://biology.usf.edu/cmmb/research/GeneAtlas%20Info/expression_console_userguide




U133 Plus 2.0. The MAS5 normalization is chosen for this analysis. Export probe set 
result and annotations as plain text file.  
Drug response prediction. Binary classification is performed for the patient’s drug 
response prediction. The prediction score for test samples are calculated by using the 







prediction score w x b
=
=- ´ +å     (7) 
Where w and b are the weight vector and bias parameters from the DrugResponse R 
packagee. The input x is the normalized patient sample gene expression data with RFE 
selected i number of features. The classification of the patient drug response is based on 
this score. We call the sample a ‘responder’ to the drug if this score is higher than 0, and 
a ‘non-responder’ to the drug if the score is lower than 0.   
2.4 TCGA RNA-seq 
We downloaded TCGA RNA-seq data, normalized gene expression quantification 
processed following the NCI mRNA analysis pipeline 
(https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/Expression_mRNA_Pipeline
/). Then we did data cleaning. Genes are removed if more than 25% of the samples have 
zero expression value. Then we download the drug response labels for all samples. Label 
1 represents responder, and 0 represents non-responder. Once complete, we randomly 




25% samples are testing data set. The data set contains two drugs, Gemcitabine and 
Fluorouracil and these two are the only ones with sufficient patients to train the machine 
learning algorithm. Within this sample set there are 92 patients profile for Gemcitabine, 
and 60 patients profile for Fluorouracil. NCI classifies patients into four stages: 
‘complete response’, ‘partial response’, ‘progressive disease’, and ‘stable disease’ 
(https://www.cancer.gov/publications/dictionaries/cancer-terms). Complete response is 
defined by the disappearance of all signs of cancer in response to treatment, although this 
does not always mean the cancer has been cured (i.e. ‘complete remission’). Partial 
response indicates a decrease in the size of a tumor, and/or the extent of cancer in the 
body, in response to treatment (i.e. ‘partial remission’). Progressive disease is defined as 
a cancer that is growing, spreading, or getting worse. Stable disease indicates that the  
cancer is neither decreasing nor increasing in extent or severity. For this thesis we 
simplify these into two classes: ‘responders’ which includes both ‘complete response’ 
and ‘partial response’; and ‘non-responders’ which includes ‘progressive disease’ and 
‘stable disease’. This data set is randomly separated into a 75% training set and a 25% 
testing set. A SVM models is built using the learning set data, and evaluated using the 
test data set. Recursive feature elimination (RFE) was performed to find the minimum set 
of features that maximized accuracy in the classification on the test dataset. The approach 
starts by removing the least relevant 100 features for the model from the bottom (lowest 
weights) of the sorted feature list. The following SVM model is built using the remaining 
features, and then again removes the 100 features with lowest weights. This process 




features are removed one at a time until the most informative set of features is obtained. 
After the RFE, the model will pick the most informative set of features yields the highest 
accuracy testing on test set. The predictive model for each drug is based on the most 
informative set of features determined for that drug. Leave one out cross-validation 
(LOOCV) is used to evaluate the performance of each of the models as previously 
described. 
2.5 Drug response data 
2.5.1 TCGA data 
Clinical trial data (12,051 records) were downloaded from TCGA for 32 types of 
cancer. The data was cleaned as described in the pre-processing methods, and 2 models 
were selected encompassing 140 patients. Corresponding Upper-Quartile Normalized 
Fragments Per Kilobase per Million mapped reads (UQ-FPKMs) from patient primary 
tumor samples were downloaded using the Genomic Data Common’s API.   
The clinical data needed to be assessed to determine which were the best drugs to 
investigate. We first defined the definition of responder as a patient who had partial or 
complete response and a non-responder as clinical progressive disease or stable disease. 
Next, to determine which drugs were viable candidates for the analysis, we required a 
sample size of at least 30 patients for the drug of interest with at least 15 for each type of 
response. The clinical trial data were then cleaned using fuzzy matching and manual 
curation to ensure consistency of drug name and formatting, and only patients on a single 




that had the highest number of patients were chosen with balance and availability of 
RNAseq data being kept in mind as a constraint.  
2.5.2 Ovarian cancer data 
 Samples of primary tumors collected from 23 ovarian cancer patients were snap 
frozen in liquid nitrogen within one minute of surgical removal and transferred to the lab 
for laser capture microdissection of cancer cells and subsequent microarray gene-
expression analysis (Affymetrix, U133Plus 2.0 arrays). Informed patient consents were 
obtained under appropriate Georgia Institute of Technology Institutional Review Board 
protocols (H14337). 
Patient responses to administered chemotherapies were monitored by 
measurement of CA-125 values prior and subsequent to treatment according to standard 
criteria [13]. Patients were considered to be responsive to treatments if their respective 
CA-125 values dropped and remain below normal values (<35) within 60 days of the start 
of chemotherapeutic treatment. 
Microarray gene expression and patient drug response data were uploaded to our 







2.6 Cluster algorithms 
2.6.1 Hierarchical Principal Component Analysis (hPCA) 
Hierarchical Cluster Analysis (HCA) is a clustering method which explore the 
organization of samples in groups and among groups depicting a hierarchy [29]. We 
applied HCA on principal components of our data set, so called hierarchical Principal 
Component Analysis (hPCA). The principal components are calculated by using an 
orthogonal transformation to convert a set of observations of possibly correlated variables 
into a set of values of linearly uncorrelated variables. This transformation is defined in 
such a way that the first principal component has the largest possible variance, and each 
succeeding component in turn has the highest variance possible under the constraint that 
it is orthogonal to the preceding components. In this project, we used first 3 principle 
components. The first 3 principle components contain 86% of all information, and we 
only gain incremental extra information if we continue to add components (i.e. adding 16 
additional components adds only 4% additional information). Then we utilized Euclidean 
distance function to calculate pairwise distance between samples, and construct clustering 
based on the pairwise distance. The result of hPCA is presented in a dendrogram, a plot 
which shows the organization of samples and its relationships in tree form. 
2.6.2 K-means clustring 
K-means clustering is a method of cluster analysis that aims to partition n 
observations into k clusters in which each observation belongs to the cluster with the 
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In equation number (10) the term x is the set of discrete structures (e.g. the set of 
all documents), and H is a Reproducing Kernel Hilbert Space (RKHS). In our k-mer data 
we can describe the frequency of k-mer appearances in the genome using the following 
equation: 
, '
, ' ' *
( , ') ( ) ( ')s s s s s s
s x s x s A
k x x w w num x num xd
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= =å å    (11) 
That is, we count the number of occurrences of every k-mer s in both x and x’ and 
weigh it by Ws. We only consider the 8-mer, so we assign other k-mer’s weights to 0. For 
K-means, we randomly chose k central points and calculate the mean of the k-mer vectors 
to represent the center points. Then sign each data point to its nearest central point by the 
distance equation number (12), and update the central points. After several iterations, we 
can find the best clustering after iterations when the central points stop changing. 
2( , ') || ' ||D X X X X= -     (12) 
2.6.3 SVM 
Support Vector Machine (SVM) is a discriminative classifier widely used in 
clustering problems. A support vector machine constructs a hyperplane or set of 
hyperplanes in a high-dimensional space, which can be used for classification. A good 
separation is achieved by the hyperplane that has the largest distance to the nearest 




training data and assign new examples to one category or the other. Models are built 
using learning set data, and evaluated using test data set. Linear support vector machine 
(SVM) is employed recursively as a classification model to separate samples into two 
classes: sensitive and resistant. The learning function is svmtrain (Matlab R2013b version 
8.2.0.701), and the kernel function is linear. The samples are represented as a vector x, 
and the two classes are divided in the dataspace by a hyperplane wx’ + b = 0 that 
maximizes the margins between the learning samples of the two classes. This margin is 
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Binary classification is performed for the test prediction. The prediction score for 







prediction score w x b
=
=- ´ +å    (9) 
Where w and b are the weight vector and bias parameters from the SVM model. 
The input x is the normalized test sample gene expression data with RFE selected i 
number of features. The classification of the patient drug response is based on this score. 
We call a sample responder to the drug if this score is higher than 0, and non-responder to 





2.7 Feature selection 
2.7.1 Principal Component Analysis (PCA) 
We utilized Principal Component Analysis (PCA) to obtain feature selection by 
use the most important components of our data sets. The principal components are 
calculated by using an orthogonal transformation to convert a set of observations of 
possibly correlated variables into a set of values of linearly uncorrelated variables. In this 
project, we used first three principle components. 
2.7.2 Sequential forward selection  
Sequential forward selection starting from an empty feature set, and creates 
candidate feature subsets by sequentially adding each of the features not yet selected. For 
each candidate feature subset, it performs 10-fold cross-validation by repeatedly calling 
fun with different training subsets of training data until there is no improvement in 
prediction. From this we choose a subset of features for the final analysis. 
2.7.3 Recursive feature selection 
Recursive feature elimination (RFE) was performed to find the minimum set of 
features that maximized accuracy in the classification on the test dataset. The approach 
starts by removing the least relevant 100 features for the model from the bottom (lowest 
weights) of the sorted feature list. The following SVM model is built using the remaining 
features, and then again removes the 100 features with lowest weights. This process 




features are removed one at a time until the most informative set of features is obtained 
[30-32].  If there are multiple models with the highest accuracy, the model with the 
fewest number of features is selected. Each model is forced to contain a minimum of 10 
probes. The predictive model for each drug is based on the most informative set of 
features determined for that drug. Leave one out cross-validation (LOOCV) is used to 
evaluate the performance of each of the models.    






Individual gene expression microarray (.CEL) files are normalized one by one 
against the original NCI 60 gene expression microarray data specific to each array (both 
Affy U133 Plus 2 and Human Exon Array) using standard quantile normalization  [33, 
34] and using the mean of each probe. This approach creates distributions for each array 




CHAPTER 3. LINEAR ALGEBRAIC AND BOOLEAN 
ANALYSIS OF GENOMIC SEQUENCES 
3.1 Abstract 
To date the comparison of genomic sequences [35] have routinely utilized shorter 
conserved regions for comparative genomics. Genomic analysis has become one of the 
major tools for disease outbreak investigations. Current phylogenetic analysis [36] 
therefore can create divergent results based on which genetic loci are utilized for this 
analysis. Sequence similarity is also commonly determined by first carrying out gap 
penalty pairwise alignments [37-41] for a set of sequences, and the similarity is 
quantified based upon this alignment. This approach, however, has limitations and is then 
primarily utilized to compare relatively conserved sequences and is also dependent upon 
the algorithm utilized to create the alignment.  This impedes genomic analysis of 
outbreaks of highly mutable viruses associated with chronic infections, such as human 
immunodeficiency virus (HIV) and hepatitis C virus (HCV). From first principles we 
here develop a framework for encoding nucleic acid sequences into fixed length sections 
(k-mers) [42, 43] which we utilize to create an invariant pairwise distance of total 
information content of over ~4,000 bacteria [44] and viruses, revealing important cryptic 
relationships not previously reported. Also, our experimental validation shows that they 






k-mer strategies have been utilized by nearly all short read DNA alignment 
strategies, including de Bruijn-type [45, 46] combinatorial mathematics and Burrows-
Wheeler transform (BWT) [47]   algorithm to efficiently align sequences. Here we 
present our software, Finch, which adds another layer of abstraction to this field by 
creating an invariant encoding heuristic for k-mers that allows for the efficient analysis 
and computation of genome similarities (https://github.com/chuang95/Finch). This 
invariant encoding framework is computable by linear algebra and also diverse Boolean, 
logic and bit operations of discrete mathematics. In addition to orthogonal transformation 
of this dataset we also show pairwise differential occupancy (which we term ktD ) of 
these data structures for hierarchical clustering of genomic sequences. To our knowledge 
we define the first global clustering of entire bacterial and viral genomes, which we 
define here as genomic topology, which led to the discovery of a number of novel cryptic 
genomic associations between species. Finch allows for this formalization of genomic 
relationships and yields an invariant pairwise differential occupancy ( ktD ) metric 
between all species based upon global information content of each genome, irrespective 
of Kingdom, and finally allows a universal complete encoding for species that was 
lacking in previous approaches.  
The exponential growth in sequencing information of organisms of all Kingdoms 
has greatly increased our understanding of the diversity of genomes and genomic 




sparse k-mer encoding system wherein genomic data is stored in an identical format that 
allows for global computations across all genomic data, regardless of homology. There 
has been a distinct lack of fundamental organization of genomic data, with primarily ad 
hoc analysis of genome similarity using subsets of evolutionarily conserved genes. We 
created a universal encoding system to store k-mer data in sparse linear vector form as 
well as an equivalent n x n square sparse matrix, which defined in Chapter II. Briefly, our 
system utilizes a sparse vector that contains 4k elements, arrayed in ascending order by 
the binary representation of the k-mer, where [A=00, C=01, G=10, T=11]. For these 
sparse vectors, we define tau (t ) by the number of non-zero elements divided by 4k  
elements, where k represents the k-mer length. We routinely also transform this binary k-
mer representation into a decimal number as seen in Figure 4. In order to optimize this k-
mer analysis we authored KAnalyze [19], which is a fast and extensible k-mer suite with 
APIs specific for this process. 
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3.3.1 Kmeans clustering on viral sequence 
We use a data set of 3 group of 8 virus: 2 different Dengue viruses, HIV-1, HIV-
2, HHV2, HHV1, HHV4, and HHV4.1. Before implement the algorithm, we plot the 
distance matrix as heat map (Fig. 5) to show the pattern of the 8 viruses. 
 
Figure 5 – Heat map of 8-mer frequency of 8 viruses. X axis are viruses and Y axis 
are 8-mer frequency. 
We chose 3 center points, and the cluster result shown in Table 1 is concordant 
with the heat map shown in Figure 5. Base on this result, we applied the kernel kmeans to 



























test data point with the 100 center point. It reduces the comparing complexity then 
comparing the test data with the whole database which is the strategy of Multiple 
Sequence Alignment (MSA). 
Table 1 – Kernel K-means clustering. 
Group Virus 
0 D1 D4 
1 HIV2 HIV1   
2 HHV2  HHV1 HHV4 HHV4.1 
     
3.3.2 Support vector machine (SVM) classification on viral and Bactria sequences  
Support vector machines (SVM) are supervised learning models with associated 
learning algorithms that analyze data and recognize patterns, used for classification and 
regression analysis. In the real clinic sample, we need to separate the virus from the 
human gene and other possible spices. Our application takes an input as training data set 
and finds a boundary between the clusters. Then take the boundary points to define a 
support vector, and finds the maximum-margin hyperplane that divides the data points 
from the other ones belong to another cluster. Also, we used kernel trick to define the 
mapping from linear from the linear feature space to non-linear space that maximizes 
separation. The Gaussian ’rbf’ kernel function is chosen here. 
First, we implemented the SVM algorithm in Matlab and apply it to virus 




with 10 random sequences with different length and GC content. The test data includes 
10 randomly chosen viruses (from NCBI) and 10 further random sequences. By using 
kernel function ’rbf’, the accuracy rises to 80 percent (Fig. 6). 
 
Figure 6 – SVM clustering (viruses in red, random sequences in green). 
Furthermore, we applied SVM algorithm to separate viruses and bacteria 
sequence. Training data set is random chosen from our database, and test is with all 1756 
viruses and 2271 bacteria sequence. The result is encouraging, and shows the pattern of 
the two groups. Also, we compare the SVM result of non-scaled (Fig. 7A, B) and scaled 
data (Fig. 7C, D). The accuracy (Table 2) of scaled data is higher because the different 
average sequence length separates the data well, however this measure does not help 
resolve true genomic complexity and the scaled versions should be utilized instead for 






Table 2 – Accuracy measurements of non-scaled and scaled test. 
Group Virus error  Bacteria error Accuracy 
non-scaled 1 42 0.99 
scaled 429 108 0.87 
 
 
Figure 7 – Non-scaled data SVM training (A) containing the training set contains 35 
viruses and 34 bacteria, and testing all 1756 virus and 2271 bacteria (B). Scaled data 
SVM training on 35 viruses and 34 bacteria (C) and SVM testing on all 1756 virus 





3.3.3 PCA and Boolean analysis 
From these first principles, we sought ways to globally analyze these sparse linear 
vectors. Using standard linear algebra approaches it is possible to complete orthogonal 
transformations of this data (Fig. 8A). In one manifestation we carry out hierarchical 
principle component analysis (hPCA) [48] of the combined genomic sparse vectors of 
multiple species, allowing for distance calculations in n-dimensional space, with the 
closest shared information content giving the smallest distance using three (or more) 
components. These first three components can then be used to create a three-dimensional 
plot of the distances between the sparse vectors for each genome sequence (Fig. 8A). In a 
similar manner, it is possible to carry out global Boolean analysis on these sparse vectors 
in a pairwise fashion. By arraying the sparse vectors in an invariant format, with full 
encoding, it is trivial to carry out pairwise discrete functions for any logic gate functions 
including [AND, OR, XOR] as seen in Figure 8B. One simple metric is the resultant 
value of the XOR Boolean operator between two sparse vectors, which we here define as 
delta tau ( ktD ), or differential occupancy, where k defines the k-mer length. We define 
the term differential occupancy as the XOR function between two sparse vectors that 
derives resultant sparse vectors followed by summing the number of non-zero elements 
and then dividing by total number of possible k-mers, which is 4k  (Chapter II Methods 
2.1.3). The more similar the two genomes the smaller the number of resultant non-zero 
elements after the XOR calculation, resulting in a number that approaches zero for the 





Figure 8 – (A) Linear algebraic forms to analyze a variety of orthogonal 
transformation / eigenvector calculations. (B) Discrete mathematics enables Boolean 
analysis using the full complement discrete function XOR.  
3.3.4 Clustering of Bacterial sequence 
 We start by carrying out the hPCA analysis of 578 bacterial genomes in the NCBI 
bacterial database.  We then plot log transformed pairwise distance of these bacterial 
genomes based on hPCA. By z-transforming the pairwise -log( ktD ) data we see a 
desirable and expected association between species-based similarities between k-mer 
encoding, and define z>=2 as closely related species. We formalize this association and 
speculate that this relationship follows a power law association (Fig. 9A), which appears 
to be inherent in natural genomic topologies of biological systems. We here show 
punctuated peaks (Fig. 9B) of closely related species within a sea of random or near 
random associations. Similarly, in calculating genomic topologies of all pairwise -log(
ktD ) species (Fig. 9C, D) will be defined as those that reside in the k-mer topology 
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within the exponential function of arrayed pairwise relationships, indicating a “null” and 
“positive” space. For these closely related species we see r2 value of 0.87 between the 
hPCA and Boolean analysis (Fig. 9E), for the species with a pairwise relationship of 
z>=2. 
 
Figure 9 – Pairwise distance. A) Sorted Log pairwise distance computed by hPCA; 
B) Unsorted Log pairwise distance computed by hPCA; C) Sorted Log pairwise 
distance computed by Boolean Analysis; D) Unsorted Log pairwise distance 
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computed by Boolean Analysis; E) Pairwise distance from hPCA and Boolean 
analysis relationship.  
 Using this ktD we apply hierarchical clustering and obtain expected clustering of 
these bacterial genomes (Fig. 10). As previously discussed, we choose k equal to 12 and; 
all 578 bacteria whole genome sequences are k-merized into matrix of integers. Then we 
build a tree on pairwise distance calculated by Boolean analysis. From Figure 10, species 
with the same name are closely clustered into the same group. For example, Figure 10 
shows a zoomed in portion of the tree where all Streptococci are grouped together. Also, 
Streptococcus thermophilus and Streptococcus pyogenes are clustered into two group. 
 As we present before, K-means, SVM, and hPCA are able to separate bacteria and 
virus sequences. However, they don’t have the ability to separate evolutionarily close 
species. Also, compared to Boolean analysis, these three algorithms required much more 
computational resources to finish the analysis of the bacteria and virus data set. The K-
means algorithm, in the extreme case, stopped without optimal clustering at maximum 
iterations (MATLAB 2014b default 100). The overall goal was to create software that 
could analyze arbitrarily large datasets, and so K-means, SVM and hPCA in practice do 
not fulfill this goal since they do not scale as well as the Boolean algorithm. The light 
weight Boolean analysis, as the clustering result shown in Figure 10, enable the 
possibility for inference of relatedness between viral samples, identification of 
transmission clusters and sources of infection, which are crucial tasks for viral outbreaks 






Figure 10 – Hierarchical clustering for bacteria. (A) Complete tree based on 
pairwise distance, and (B) Zoomed in portion of the hierarchical clustering, 









3.3.5 Clustering of HIV sequences 
In another application of Boolean analysis, we performed clustering of HIV 
sequences. The sequences that we analysed were obtained from the HIV sequence 
database (https://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html). Based on the 
origins of the samples, we selected four groups: Asia, Africa, Europe, and America. k-
merized sequences, with k equal to 12, were used to calculate Boolean analysis pairwise 
distance. First, we used the data without performing any noise reduction. We then plotted 
the clustering, using D3 JSON, based on differential occupancy. Figure 11A shows that 
there is no clear classification among the samples. The reason for this mis-clustering, is 
that this data was generated from different labs around the world and many of the 
genomes had variable length regions in the beginning and end. In order to account for this 
and attempt to remove this issue we applied a noise reduction approach before Boolean 
analysis. First, we k-merized the sequences and aggregated them into one matrix (termed 
k-matrix), in which the rows contain k-mers and the columns are samples. Then, we 
counted the number of times each k-mer was present in the 197 samples. If one of the 
sample sequences contained the k-mer, we counted it as 1 and the highest count number 
possible for each row, in this example, was 197. If a k-mer was present in less than 5 
samples (i.e. 5/197 or 2.54%), we removed this row/k-mer from the matrix to effectively 
buffer against noise in this data set. The threshold number 5 is is approximately twice the 
standard deviation, (i.e. z-score of 2) (Figure 11C). After noise reduction, we applied 




occupancy ( ktD ). Four groups are now separated as shown in Figure 11B, and we can 
see a much clearer clustering pattern among samples based on their origin. 
  
Figure 11 – D3 JSON plot for pairwise distance of HIV genomes generated by 
calculating differential occupancy. A) plot without noise reduction. B) plot after 
noise reduction. C) z-score of 12-mers counts among 197 HIV genomes. 
3.3.6 Clustering of HCV sequences 
There are several studies on HCV outbreaks. One of the most recent successes is 
Viral Outbreak InferenCE (VOICE) [49-51], which infers genetic relatedness and 
transmission clusters. We applied our Boolean analysis algorithm on a benchmark HCV 
data set they provided, which is a collection of HCV intra-host populations sampled from 
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335 infected individuals. The data consist of 335 intra-host HCV populations, including 
142 populations from 33 outbreaks reported to CDC in 2008–2013 and 193 populations 
from infected individuals without any known epidemiological relationship, all obtained 
from national collections and other research projects [49]. Each outbreak collections 
contain from 2 to 19 samples. For all samples, HCV hypervariable region 1 (HVR1) was 
sequenced. All viral sequences represent a fragment of the E1/E2 genomic region of 
length 264 bp. Viral populations from two samples are genetically related if they belong 
to the same outbreak and unrelated, otherwise. The genetic relatedness is validated on the 
union of collections containing all outbreaks and unrelated samples. There are 24,833,479 
pairs of samples, and 99,029 of them are related. We utilized our algorithm to distinguish 
related versus unrelated HCV sequences and compared our results to the VOICE 
algorithm. We obtained 95.38% accuracy, 91.70% sensitivity, and 95.39% specificity for 
the detection of related versus unrelated sequences in a pairwise comparison (Fig. 12). 
This accuracy is substantially improved over the previously reported <93% accuracy of 






Figure 12 – Histogram of the Finch HCV analysis.  
3.3.7 Clustering of Plasmodium malariae and P. ovale genome sequences 
We applied our Boolean analysis on a classification of Plasmodium malariae and 
P. ovale genomes. A reference genome of P. malariae was produced from clinically 




























assembly surpasses available draft genome data for P. malariae [53], especially in terms 
of contiguity allowing large-scale structural changes to be accurately determined. 
Additional draft genomes for both species of P. ovale [54] were assembled from P. 
falciparum co-infections and the genome of P. reichenowi, which is a chimpanzee-
infective species.  
Boolean analysis pairwise distance is calculated on k-merized sequences, with k = 
47. As shown in Figure 13, P. malariae is separated from P. ovale. Also, two mouse-
infective species, P. berghei and P. chabaudi are grouped into one branch away from 
other species. The most interesting finding is human-infective specie P. falciparum and 
chimpanzee-infective specie P. reichenowi are classified together. To investigate host-
specific adaptation of parasites to human and chimpanzee hosts, we compared P. 
malariae to P. malariae-like and we found lower levels of nucleotide diversity in the 
human-infective species than in the chimpanzee-infective species. This mirrors the lower 
levels of nucleotide diversity in the human parasite P. falciparum than in its chimpanzee-
infective relative P. reichenowi. In both cases, the lack of diversity in human-infective 
species suggests recent population expansions. There is a study using additional samples 
to calculate standard measures of molecular evolution, they are able to identify a subset 
of genes under selection in both P. malariae and P. malariae-like and in an earlier study 
of P. falciparum and P. reichenowi, showing some conservation of selection pressures in 
Plasmodium lineages and suggesting host- specific adaptation of parasites to human and 






Figure 13 – Hierarchical clustering for Plasmodium species. Hierarchical clustering 
was generated by differential occupancy for Plasmodium whole genome sequence.  
3.3.8 Clustering of Non-O157 STEC whole genome sequences 
 We applied Boolean analysis algorithm on whole genome sequencing of non-
O157 Shiga toxin-producing Escherichia coli (STEC) strains [55, 56]. In the United 
States, according to CDC (https://www.cdc.gov/ncezid/dfwed/pdfs/national-stec-
surveillance-overiew-508c.pdf), an estimated 168,698 non-O157 infections occur each 
year, which is more than the number of cases (estimated at 96,534) caused by STEC 





















O157. Among the non-O157 STEC strains, serogroups O26, O111, and O103 are 
considered the most clinically important and frequently identified non-O157 STEC 
strains in severe diseases and food-borne outbreaks. In Meng’s study [57], seven 
housekeeping genes (aspC, clpX, fadD, icdA, lysP, mdh, and uidA) extracted from 
genomes were selected for multi-locus sequence typing (MLST) analysis. They exclude 
strains 4865/96 (O145:H28), 101-1 (O?:H10), 5.0959 (O121:H19), DEC12B (O111:H2), 
and E110019 (O111:H9) because at least one of the selected gene alleles was either 
absent or only partially present. Here, instead of extracting genes, our program uses 
whole-genome sequence. We analyzed all strains available, and generated a similar tree 
by clustering on our Boolean analysis pairwise distance. k-mer files were generated by 
Kanalyze[19], and utilized the parameter k = 47 for this analysis. As Shown in Figure 14, 






Figure 14 – Hierarchical clustering generated by differential occupancy for non-
O157 E. coli whole genome sequence.  
3.4 Discussion 
 Historically it was not always possible to adequately compare complete genomic 
content between two species dues to the inability to align dissimilar sequences. We 
















































designed a universal system, termed genomic topology in this dissertation, that enables 
any two sequences to be compared in a fair and simple way, and allows for very different 
sequences to obtain a definite pairwise score. Using our analysis it does indeed appear 
that there is a specific power law effect that describes the overall genomic topology 
between species, with a sharp exponential decay in genomic topology between two 
different species. This, again, has been suggested but we feel that our result is one of the 
clearest attempts to show such a genomic topology. 
 We demonstrate the ability to cluster similar species from first principles using 
genomic topology calculations without additional levels of abstraction. We show that 
optimized discrete calculations on global k-mer space qualitatively work as well as 
traditional linear algebra-based orthogonal transformations eigen value-based principle 
component analysis, and in certain use cases better than these other algorithms. Although 
laboratories can and will use analysis of higher levels of abstraction such as the case of 
PCA and multiple dimensional scaling, it is our opinion that it is easier to intuit 
intellectually discrete calculations of these higher order matrices verses considering the 
eigen vector space. An important distinction, which is always troubling with PCA and 
MDS types of analyses is that the origin of the variation is lost in the calculation, with the 
inability to determine the origin of the variation. Discrete systems do not face such 
restrictions, and our system creates the ability to real time cluster and reveals the origin of 
the variation at the same time, creating a use case that is relevant to pharmacological 
development. It is not lost on us that a similar encoding system using k-mer/n-tuples can 




between such genomic and proteomic data will also be useful in comparative analysis of 
species. Indeed, philosophically, this brings to the fore arguments for such numerical 
taxonomy approaches whereby additional data streams can be added into such analysis, 
allowing for quantitative assessments of species, including morphological, developmental 
and other encoding. It should be noted that this is not closed to inter-species analysis, 
indeed use cases abound that make intra-species analysis informative. Examples include 
analysis of virulent E. coli strains, or viral outbreaks scenarios. Our laboratory is working 
closely with multiple Centers for Disease Control branches to implement such analysis to 






CHAPTER 4. OPEN SOURCE MACHINE LEARNING 
ALGORITHMS FOR THE PREDICTION OF OPTIMAL CANCER 
DRUG THERAPIES 
4.1 Abstract 
 Precision medicine is a rapidly growing area of modern medical science and open 
source machine-learning codes promise to be a critical component for the successful 
development of standardized and automated analysis of patient data.  One important goal 
of precision cancer medicine is the accurate prediction of optimal drug therapies from the 
genomic profiles of individual patient tumors. We introduce here an open source software 
platform that employs a highly versatile support vector machine (SVM) algorithm 
combined with a standard recursive feature elimination (RFE) approach to predict 
personalized drug responses from gene expression profiles. Drug specific models were 
built using gene expression and drug response data from the National Cancer Institute 
panel of 60 human cancer cell lines (NCI-60). The models are highly accurate in 
predicting the drug responsiveness of a variety of cancer cell lines including those 
comprising the recent NCI-DREAM Challenge. We demonstrate that predictive accuracy 
is optimized when the learning dataset utilizes all probe-set expression values from a 
diversity of cancer cell types without pre-filtering for genes generally considered to be 
“drivers” of cancer onset/progression. Application of our models to publically available 
ovarian cancer (OC) patient gene expression datasets generated predictions consistent 




“open source”, we hope to facilitate its testing in a variety of cancer types and contexts 
leading to community-driven improvements and refinements in subsequent applications. 
4.2 Introduction 
 The sequencing of the human genome, genome-wide association studies 
(GWAS), quantitative trait loci (QTL) mapping, and similar research initiatives over the 
past few decades have greatly increased our understanding of the molecular pathways 
associated with human diseases. These efforts have significantly benefited from the 
liberal sharing of data and open-source scripts utilized for these efforts. Over the last few 
years, there has been a number of alternative machine-learning (ML) approaches 
employed in personalized cancer drug prediction, each associated with variable degrees 
of success [10, 58, 59]. For example, pRRocphetic [11] is a recently designed R package 
designed to run the entire learning and subsequent calling of patient data. Other recent 
contributions include the Bioconductor [60] package SCAN that allows for single-sample 
array normalization for precision medicine workflows. While a number of ML 
applications for precision medicine have benefited from community assessments of 
predicted drug response [e.g., [10, 58]), such efforts have not always shared code, and for 
the majority of efforts only the organizers of the community assessment exercise were 
able to see the source code to evaluate each independent solution. This is unfortunate 
because the open sharing of code has been demonstrated to be a significant catalyst in the 
optimization of ML applications as in the Large Scale Visual Recognition Challenge 




 We present here an open source software platform using a highly versatile support 
vector machine (SVM) algorithm that utilizes standard recursive feature elimination 
(RFE) methods to predict cancer drug response. In pilot applications, we utilized publicly 
available datasets from NCBI Gene Expression Omnibus (GEO) [63] that we formatted 
and the array files were partitioned into learning sets and experimental sets. Each 
individual array is accessible as a .CEL file with individual identifiers at a publically 
accessible GitHub site that outlines the learning, validation and test sets employed in our 
initial studies (https://github.com/chuang95/KEA_DrugResponse). Also available at this 
GitHub site are general procedures for open application of our software to additional 
datasets (https://github.com/chuang95/KEA_DrugResponseLearning). We have 
employed the algorithms to explore the effect of a variety of alternative learning datasets 
on predictive accuracy leading to several unanticipated findings. First, predictive 
accuracy was significantly improved when microarray probe level expression data rather 
than average gene expression values were employed in the model building process. 
Second, predictive accuracy was improved when models were built upon a diversity of 
cancer types. Third, the pre-filtering of learning datasets based upon preconceived 
biological models significantly reduces predictive accuracy. Application of our optimized 
models to publically available ovarian cancer (OC) patient gene expression datasets 
generated predictions highly consistent with observed responses to a variety of drugs. By 
providing true open access to our software, we seek to encourage additional 




approaches leading to the development of optimal ML-based strategies for personalized 
cancer medicine. 
4.3 Result 
4.3.1 Support Vector Machine (SVM) model building and recursive feature selection 
algorithm  
 A variety of ML techniques and strategies have been employed in the quest for 
optimal accuracy, sensitivity and specificity in drug response predictions. In this work, 
we utilize an SVM approach paired with recursive feature elimination (RFE). SVM has 
been successfully applied in a variety of biological applications in recent years (e.g., 
[64]). Our SVM models were built using gene expression 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32474) (Supplementary table 
1) and drug sensitivity profiles (https://wiki.nci.nih.gov/display/NCIDTPdata/NCI-
60+Growth+Inhibition+Data) (see also Supplementary table 2) of the NCI-60 panel of 
human cancer cell lines. Predictive models were built for seven drugs often employed in 
the treatment of ovarian cancer (carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, 
doxorubicin, gefitinib). The drug sensitivities (GI-50) of the NCI-60 cell lines 
approximate a normal distribution (Fig 15A; Fig 30). For our learning dataset, we 
conservatively excluded cell lines displaying GI-50 values within ±0.50 SD of the mean. 
The test dataset, however, was selected from all cell lines. In all cases, cell lines used to 





Figure 15 – An SVM-RFE predictive model of carboplatin sensitivity for NCI-60 cell 
lines.  (A) Ranked display of -log transformed GI-50 values for carboplatin for each 
of the NCI-60 cell lines. Blue circles = carboplatin resistant cells; red circles = 
carboplatin sensitive cell lines. Cell lines with GI-50 values within ±0.5 SD of the 
mean (green circles) are less reliably classified as resistant or sensitive and were, 
thus, not employed in learning datasets. Test sets were selected from cell lines across 
the entire distribution; (B) Evolution of accuracy of predicted response to 
carboplatin using SVM-RFE selection for gene probe classifiers; (C) Visualization of 
the optimal separation between carboplatin sensitive and resistant NCI-60 cell lines. 
The X-axis is the optimal weight vector (prediction score) of the SVM model for 
carboplatin; the Y-axis is the -log transformed GI-50 values for carboplatin. 
SVM models built upon large datasets typically contain uninformative features, and 
a number of feature selection methods have been developed to identify subsets of features 
with optimal predictive accuracy [65-67]. We employed a previously described RFE [68, 
69] method to select for features (gene probe sets) that optimally distinguish cells 
predicted to be sensitive to a drug from those that are not. The RFE method starts by 
discarding the least relevant features of the model from the bottom of the sorted feature 
list (Supplementary table 3). The subsequent SVM model is built on the remaining 
features and again, features with the lowest weights are removed. This process proceeds 
in a recursive manner until a minimal subset of features is identified that is essential to 
maintain optimal predictive accuracy.  For example, Figure 15B depicts the evolution of 
predictive accuracy using SVM-RFE feature selection for increased sensitivity to 
cell line
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carboplatin (see Fig 31 for feature selection of the other drugs). In this case, initial 
removal of uninformative features increased accuracy due to the elimination of features 
that negatively interact with predictive accuracy. Our SVM-RFE approach compares 
favorably with other commonly employed methods of feature selection (see Fig 31).  
 The minimal number of informative features associated with optimally predicted 
responsiveness to the seven drugs modeled in this study ranged from 10 to 32 
(Supplementary table 4). While the biological contribution of the majority of these genes 
to drug responsiveness is currently unknown, potentially informative trends are often 
apparent.  For example, several of the most informative genes predictive of carboplatin 
sensitivity have been directly or indirectly implicated with apoptosis (Supplementary 
table 5), a cellular function known to be induced in response to carboplatin treatment 
[70].  
 The SVM models generate drug prediction scores for each cell line. Scores higher 
than "0" indicate a predicted sensitive response, less than "0" a predicted resistant 
response (e.g., see Fig 15C, X-axis). The overall accuracy, specificity and sensitivity are 
evaluated by leave-one-out cross-validation (LOOCV). The SVM computed predictive 
scores are plotted against observed GI-50 values to graphically display the accuracy of 
each model. For example, the quadrant plot for carboplatin (Fig 15C) shows that the 
SVM model is 84% accurate across the NCI-60 test dataset. The predictive accuracies of 
each of the seven models ranged from 75% to 85% (see Fig 32 for predictive accuracies 




4.3.2 Building SVM-based models across a variety of cancer types improves predictive 
accuracy 
 While feature selection methods are designed to identify the most informative 
features by systematically eliminating less informative ones, the predictive accuracy of 
ML models is heavily dependent on the presumption that the original learning dataset 
encompasses the full spectrum of features potentially relevant to the predicted variable 
[10]. The selection of appropriate learning datasets for building predictive models of 
cancer drug response is especially challenging because a full understanding of the 
molecular processes underlying cancer onset/progression has yet to be attained [71]. For 
this reason, subjective limitations in the scope of data employed in learning datasets may 
negatively affect predictive accuracy of derived models if informative features are 
inadvertently excluded. For example, it is frequently assumed that models designed to 
predict optimal therapies for a particular cancer type should appropriately be built using 
learning datasets derived exclusively from that same type of cancer. However, a growing 
body of evidence indicates that the molecular pathways underlying cancer 
onset/progression are not necessarily defined by a tumor's tissue of origin [72]. Thus, a 
gene expression pattern associated with a particular cancer type may underlie cancer 
development in other cancer types as well.  
 To explore this issue, we compared the relative accuracies of two SVM-derived 
models designed to predict response to the commonly prescribed cancer drug carboplatin. 
The respective models were built using gene expression profiles and drug response 




18 cell lines were representative of only two types of cancers (lung and melanoma) while 
in the other case, the 18 cell lines were randomly selected to be representative of all 9 
types of cancer comprising the NCI-60 dataset (lung, colon, breast, ovarian, leukemia, 
renal, melanoma, prostate and CNS). As shown in Figure 16A, the model built using data 
from the 9 cancer types was more accurate in predicting carboplatin sensitivity (87.5%) 
than the model built upon only two cancer types (75.0%) (Fig 33). This finding is 
consistent with growing evidence that the molecular basis of individual cancers may not 
necessarily be defined by tissue of origin [17]. In addition, the fact that variation in gene 
expression levels is typically greater among multiple cancer types (Fig 34) may be an 
additional relevant factor since the predictive accuracy of ML models is well known to 





Figure 16 – The influence of learning datasets on the predictive accuracy of SVM-
RFE models. (A) Comparison of predictive accuracy (ROC curves) for two SVM 
models of response to carboplatin using a learning dataset derived from 2 cancer 
types (lung, melanoma) vs. 9 cancer types (brain, breast, lung, leukemia, renal, 
colon, ovarian, prostate and melanoma). In each case, the data were derived from a 
total of 18 cell lines. The results indicate that the model built using learning set data 
from 9 cancer types generates a more accurate prediction (see also Fig 33); (B, C, D) 
Prediction of the sensitivity of breast cancer cell lines to doxorubicin. In one case, 
the model was built using a learning dataset comprised of average gene expression 
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the expression values of all gene probes. The results demonstrate that the model 
built using probe set data is more accurate than the model built using average gene 
expression data; (C) prediction score accuracy using average gene expression 
values; (D) prediction score accuracy using expression values of all gene probes 
(Red circles = drug sensitive training set; Blue circles = drug resistant training set; 
Black diamonds = breast cancer cells test set). 
4.3.3 The averaging of microarray probe set expression values reduces predictive 
Another way in which the information content of learning datasets may be 
compromised is by the employment of average rather than raw experimental values. For 
example, Affymetrix and other microarray gene expression systems typically incorporate 
multiple probe sets per gene, thereby providing the possibility of monitoring differences 
in levels of alternative splicing and other post-transcriptional expression variants (e.g., 
Fig 34). While the use of average gene expression values may be appropriate for many 
applications, the loss of information associated with the use of such average values in 
learning datasets could negatively affect the accuracy of drug prediction algorithms if, for 
example, rare splice variants turn out to be particularly informative features.  
To test this possibility, we compared the relative predictive accuracies of two 
SVM-based algorithms developed to predict the sensitivity of the set of breast cancer cell 
lines recently employed in the NCI-DREAM Challenge to the drug doxorubicin [1]. In 
one case, we employed the average Affymetrix gene expression dataset that was provided 
to the Challenge participants (https://www.synapse.org/#!Synapse:syn2785783). In the 
other case, we downloaded and employed the original probe data as our learning set 
(ArrayExpress E-MTAB-181, http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-




using the probe set data is substantially more accurate (89%) in predicting the sensitivity 
of the breast cancer cells lines to doxorubicin than the model (78%) built using the 
averaged gene expression values. 
4.3.4 Pre-filtering of learning datasets can reduce predictive accuracy 
Some methods to assess risk of cancer progression and/or severity focus almost 
exclusively on genes previously identified as drivers of cancer onset/progression [73].  
The advantage of such data pre-filtering is a reduction in the complexity of downstream 
analyses but, as discussed above, it may also negatively impact the accuracy of derived 
predictive models if the truncated datasets do not encompass all genes associated with 
drug sensitivity.  
To explore this question, we compared the predictive accuracy of two SVM-based 
models using the above breast cancer cell line data. In one model, the learning dataset 
consisted of expression patterns of 297 genes previously implicated in cancer 
onset/progression [74] (http://foundationone.com/docs/FoundationOne_tech-info-and-
overview.pdf). In the second model, the learning dataset included probes of all 
significantly expressed genes (Supplementary table 1). The models built using the pre-
filtered data from the 297 genes were substantially less accurate (59.6%) in predicting 





Figure 17 – Pre-filtering of learning datasets can reduce the accuracy of predictive 
models. Shown is the predicted sensitivity of breast cancer cell lines to doxorubicin 
by two SVM models built using different learning datasets. In one case, the model 
was built using a learning dataset limited to the expression of 297 genes previously 
associated with cancer onset/progression [19]. In the other case, the model was built 
using a learning dataset drawn from all significantly expressed genes 
(Supplementary table 1). The results indicate that pre-filtering of the learning 
dataset to only include gene expression values of previously identified cancer related 
genes reduces predictive accuracy. (A) Quadrant plot of SVM predicted sensitivity 
to doxorubicin vs. observed sensitivity to doxorubicin of model built using a 
learning dataset pre-filtered for genes previously associated with cancer 
onset/progression; (B) Quadrant plot of SVM predicted sensitivity to doxorubicin 
vs. observed sensitivity to doxorubicin of model built using all gene expression data 
(Supplementary table 1); (C) ROC curves of the two models showing reduced 
predictive accuracy associated with the pre-filtered learning dataset (Red circles = 
drug sensitive training set; Blue circles = drug resistant training set; Black 
diamonds = breast cancer cells test set). 
4.3.5 Model applications to human cancer datasets 
While our predictive models were established using gene expression and drug 
sensitivity data from human cell lines, we were interested in conducting preliminary 
evaluations of the models' ability to predict the response of human cancer patients to 
chemotherapeutic treatments. Toward this end, we downloaded three independently 
derived (Affymetrix) gene expression datasets of 273 ovarian cancer patient tumors from 
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http://www.ncbi.nlm.nih.gov/gds). The expression values for each individual array were 
normalized back to the NCI-60 gene expression data matrix.  
Using these data, we employed our models to predict the response of the 273 
cancer patients to cisplatin, doxorubicin, paclitaxel, carboplatin, docetaxel, gemcitabine 
and gefitinib. For example, Figure 18A and B display the predicted response of two 
randomly selected patients from the GEO data set. One of the patients (Fig 18A) is 
predicted to respond favorably to the standard first-line therapy (carboplatin/paclitaxel) 
while the second patient (Fig 18B) is not. Interestingly, the patient predicted not to 
respond to first line therapy, is predicted to respond favorably to gemcitabine. 
Unfortunately, the observed response of these individual patients to therapy is not 
available. However, the collective response of ovarian cancer patients to the seven drugs 
analyzed in these studies has been previously reported (Supplementary table 6). To 
compare the collective predictive accuracy of our models to the collective observed 
response rates, we combined the predictive sensitivities of the 273 patients comprising 
the 3 GEO datasets and displayed the results as a distribution of the combined SVM 
predicted scores (Fig 18C).  The results indicate that while at least some patients are 
predicted to respond to each of the seven drugs, the vast majority (75%) of patients are 
predicted to respond favorably to carboplatin (Fig 18C), followed closely by gemcitabine, 
cisplatin (58%) and paclitaxel (56%). Of interest is the fact that carboplatin, given 
concurrently with paclitaxel, is the current first-line chemotherapy for ovarian cancer 
patients, with approximately 75-80% of patients being responsive to this combination 




response is carboplatin. Gemcitabine is commonly given as a second-line chemotherapy 
for OC and has been found to be of moderate clinical effectiveness, in line with our 
predictive models [76]. Figure 18D displays the linear regression between the predicted 
response rates to the seven chemotherapeutic drugs by our models and the observed 
response rate from clinical studies (Supplementary table 6). The overall predictive 
accuracy of our models in this dataset is > 80% (r2 = 0.8201).   
  
Figure 18 – Individual and aggregate prediction of response to chemotherapeutic 
drugs. The SVM algorithms output binary classifications for each drug 
(sensitive/resistant) established through a decision function that numerically 
separates cancer cells predicted to respond to the drug (positive score) from those 
predicted to be non-responders (negative score). (A) The predicted response of an 
individual patient (GSM516724) to seven chemotherapeutic drugs. This patient is 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and paclitaxel (score 3.20). (B)The predicted response of a second individual OC 
patient (GSM516801) to seven chemotherapeutic drugs. The patient is predicted 
NOT to respond favorably to the first line therapies of carboplatin (score -0.28) and 
paclitaxel (score -2.53). (C) Density plot of aggregate prediction scores for 3 GEO 
data sets of 273 ovarian cancer patients and the predicted group response rate for 
each drug. (D) Scatter plot of the predicted group response rates vs. the observed 
group responses of OC patients to seven chemotherapeutic drugs (Linear regression 
p value = 0.0031, r2 = 0.8201) (Supplementary table 6). 
4.4 Discussion 
 A primary goal of personalized cancer medicine is the accurate prediction of 
optimal drug therapies based upon individualized molecular profiles of patient tumors 
[77]. In an ideal world, such predictions are based upon firmly established cause and 
effect relationships between identified molecular aberrations and specific aspects of the 
onset and progression of the disease. An example is the well-established relationship 
between constitutively active Bcr-Abl tyrosine kinase (TK) expression and the leukemic 
phenotype associated with CML (chronic myelogenous leukemia) [78]. Patients 
identified with this molecular aberration are effectively treated with targeted TK 
inhibitors that work to reduce the elevated activity and restore regulatory balance to the 
cell. Regrettably, the underlying molecular causes of most tumors are, as yet, not as well 
understood as for CML. This has leadled to growing interest in the application of ML 
approaches to the prediction of optimal drug therapies [73]. ML-based predictive models 
are not predicated upon knowledge of underlying cause and effect relationships but rather 
on the identification of significant correlations between specific components of tumor 




 The open source availability of ML prediction algorithms provides the research 
community with unique opportunities for creative modifications and improvements of 
existing algorithms not otherwise possible. For example, open sharing of code has been 
critical to improvements in ML approaches to image recognition [61, 62].  
 Despite the documented advantages of the open sharing of code, to date, the 
practice has been extremely limited within the field of cancer drug prediction. For 
example, there is a notable lack of GitHub, Sourceforge, R Bioconductor and other online 
repositories of cancer drug prediction applications in contrast to the resources available 
for other ML applications such as the Large Online Image (LOI) repository competitions 
where alternative computational solutions are openly deposited [62]. We believe that 
making cancer drug prediction algorithms open source could result in similar benefits in 
the field of personalized cancer medicine.  
 Toward that end, we present here an open access support vector machine (SVM)-
based algorithm for the predictive response of cancers to seven widely employed 
chemotherapeutic drugs. The algorithm combines a standard SVM approach with a "one-
by one" data normalization pipeline. We have employed the algorithm to explore the 
effect of a variety of alternative learning datasets on predictive accuracy leading to 
several unanticipated findings. For example, although it may seem intuitive that drug 
predictive models for a specific type of cancer should optimally be built upon data from 
the same cancer type, our results suggest that this may not always be the case. The 
predictive accuracy of the drug response of a particular cancer type was significantly 




finding is consistent with growing evidence that molecular signatures of optimal cancer 
drug response are not necessarily defined by the cancer's tissue of origin [72].  
 Microarray platforms typically monitor gene expression levels using multiple 
probe sets. This allows discrimination between the expression patterns of alternative 
splice variants and/or other gene transcript isoforms. Most often, the input expression 
data for the building of ML predictive models utilizes average expression values across 
all gene probes. We found that higher accuracy is attained when all probes are 
incorporated in the learning dataset presumably because some isoforms are more 
informative than others with respect to drug response and this information is lost or 
diluted when individual probe data are combined in an average value.   
 Personal cancer drug therapy, as currently envisioned, involves the targeted 
inhibition of one or more "cancer driver" genes, i.e., genes that have been previously 
identified as playing key roles in cancer onset and progression. For this reason, the 
molecular profiles of putative cancer driver genes or other pre-defined subsets of genes 
are often considered sufficient for the accurate prediction of optimal drug therapies. We 
found that predictive accuracy can, in fact, be significantly reduced when expression 
profile datasets are pre-filtered prior to ML-based model building. This result suggests 
that genes involved in cancer drug response are not necessarily limited to those involved 
in cancer onset even when the drug in question is designed to target a specific group of 
driver genes. This also can be referred to over fitting problem. At this point, our model 
utilized linear kernel support vector machine as cluster and performed feature elimination 
on our learning set, NCI 60 cell line microarray. The most common way to tune this 




elimination, we tune the model by try different C from range [0.1:0.1:1 2:1:10 
20:10:100], and select the best C for each step. Figure 19A shows the performance of 
best model by tuning C yields accuracy better than 95%. However, when we test the 
optimized model on clinical patients (Fig. 19B), all sample are classified into one 
category, either extreme responder or extreme non-responder. Obviously, the model is 
over fitted for our learning set, NCI 60 cell lines data set. Over fitting is common 
problem in machine learning problems, and our learning set is a well-maintained clean 
tumor cell line data set. To avoid this type of over fitting, we need a larger data set, 
especially clinical patient microarray gene data. 
 
Figure 19 – Model optimization by tuning boxconstraint parameter C for SVM. A) 
Performance of optimizing model on NCI 60 cell lines data set. B) Optimized model 




























































































































































  Although our models were built using the publically available NCI-60 cancer cell 
line datasets, we are encouraged that predictions using publically available human patient 
datasets are generally consistent with clinical observations. By making our predictive 
models open source, we hope to encourage the testing of predictions in additional human 
datasets representative of a diversity of tumor types. we test our model on non-small cell 
lung cancer (NSCL) patients (GSE19804). Figure 20 shows the density of predicted 
scores for both NSCL cancer and ovarian cancer patients (GSE30161). By comparing 
these two together, we can see the response rate of drug Carboplatin for NSCL patient is 
lower than it for ovarian cancer patients. This indicates that the drug Carboplatin is not 
effective on threating NSCL cancer patients as it on ovarian cancer patients. According to 
NCI, this is true. Because Carboplatin is mostly used on ovarian cancer, not NSCL 
cancer. To move to a new chapter, you must tell Word that you are moving on to a new 
page. To prove our algorithm can be used for other type of cancer, we are going to build 






Figure 20 – Model prediction scores on non-small cell lung cancer patients and 
ovarian cancer patients. 
 Another approach to optimize our model is building a model for all drugs. We 
start by test our models for each drug on other drugs in our database. As shown in Figure 
21, some models did good job predicting drug response on other drugs. For example, 
models of Erlotinib and Gefitinib perform well on each other. They both predict over 
75% accuracy on each other testing set. That’s because they are similar target drugs. 
However, most models perform poor on other drugs. Different model of drug selected 
different subset of most informative genes, because drugs target different cancer 
pathways. One model to rule all drugs seems hard to achieve, but one model with 
dynamic selection of genes for different combination of therapies maybe the next step of 


















Figure 21 – An SVM-RFE predictive model of carboplatin sensitivity. 
 In summary, our findings demonstrate that significant improvements can be made 
in the predictive accuracy of ML-based algorithms by modulating the format and/or type 
of learning datasets employed in the model building process. This finding is likely to be 
relevant regardless of the type of ML approach employed. While our results illustrate 
several paths by which the predictive accuracy of our ML-based cancer drug prediction 
algorithm was improved, these and additional possibilities need to be tested with larger 
and more extensive datasets. We believe that such goals are most effectively attained by 
communal efforts where the research community is provided open access to the 
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88.37 78.79 63.64 51.43 46.15 70.83 60.61 47.06
cross drug model evaluation






comparisons with alternative methods can be made [79]. Toward this end, we currently 
provide an open source R package and pipeline for application of our prediction methods 
(https://github.com/chuang95/KEA_DrugResponse). In addition, a user-friendly web 
server is currently under construction that will further enhance public access to our 
methods. It is our hope that through community sharing of this and other open source 
cancer drug prediction algorithms and associated data formatting/normalization 






CHAPTER 5. MACHINE LEARNING PREDICTS INDIVIDUAL 
CANCER PATIENT RESPONSES TO THERAPEUTIC DRUGS 
WITH HIGH ACCURACY  
5.1 Introduction  
 A primary goal of precision cancer medicine is the accurate prediction of optimal 
drug therapies based upon the personalized molecular profiles of patient tumors [80]. 
Ideally, such predictions are based upon well-established molecular cause-and-effect 
relationships that are disrupted in cancer cells. A notable example is the targeted 
inhibition of the Abl tyrosine kinase protein in the treatment of chronic myelogenous 
leukemia (CML) [81]. Unfortunately, the molecular processes underlying most cancers, 
and especially solid tumors, are currently not as well understood as for CML [82]. An 
alternative path to accurate predictions is based simply on observed, highly-significant 
correlations, even when the underlying causal connections are unknown or incompletely 
understood.  
 The foundation of accurate correlative predictions is built upon extensive and 
reliable bodies of data, and the volume of cancer-relevant data being generated and 
computationally stored on a daily basis vastly exceeds what could be even imagined only 
a few decades ago. For example, the volume of cancer-relevant molecular data being 
generated by genomic studies alone (DNA sequencing, RNA expression, etc.) is currently 
doubling about every 6-7 months and, within the next decade, is estimated to constitute 




 The search for highly significant correlations in cancer-relevant datasets is a task 
ideally suited to computers and specifically to a branch of artificial intelligence called 
machine learning (ML). Towards that end, a number of ML-based approaches have been 
developed in recent years that input the genomic profiles of individual patient tumors and 
output predictions of optimal drug responses based upon correlations embedded within 
previously established datasets [84].  We recently introduced open source access to a 
support vector machine (SVM)-based algorithm that inputs gene expression profiles of 
cancer cells to predict the response of individual cancers to chemotherapeutic drugs [85].  
We previously employed this algorithm to predict the sensitivities of 273 ovarian cancer 
patients to seven commonly prescribed drugs [85]. These predictions were shown to 
correlate significantly with previously reported response rates of independent groups of 
ovarian cancer patients to these drugs (Linear regression p value = 0.0031, R2 = 0.8201). 
We present here the use of SVM-based algorithms to predict the responses of individual 
cancer patients to a variety of standard-of-care chemotherapeutic drugs from gene-
expression profiles (RNAseq or microarray) of patient tumors 
(https://github.com/chuang95/KEA_DrugResponseRNA-seq). The accuracies of the 
models to predict responses to a variety of drugs across 175 patients ranged from 81.5% 
to 83.6%. The potential clinical utility of our SVM-based approach, particularly with 









5.2 Results  
5.2.1 The response of individual cancer patients to gemcitabine or 5-fluorouracil 
therapy is predicted with >80% accuracy  
To assess the accuracy of our SVM-based algorithms to predict drug response on 
an individual patient basis, we first employed matched sets of gene-expression and drug-
response profiles from The Cancer Genome Atlas (TCGA) database (TCGA 
https://cancergenome.nih.gov/). The TCGA database is comprised of 2.5 petabytes of 
data including the genomic profiles of tumor and matched normal tissues from more than 
11,000 patients representing 33 types of human cancers. Despite the impressive size of 
this dataset, we were limited because we require not only gene-expression profiles of 
patient tissues but detailed information on each patient's individual response to 
chemotherapy as well. Since the availability of such correlated sets of data for specific 
cancer types is currently limited, we combined TCGA data of patients associated with a 
diversity of cancer types but for which the response profiles to two commonly employed 
chemotherapeutic agents, gemcitabine (GEM) and 5-fluorouracil (5-FU), have been well 
documented. In this way, we were able to establish a dataset comprised of expression 
profiles (RNAseq) and drug response profiles of 152 patients (92 treated with 







Table 3 – Number and types of cancer patients responding to gemcitabine or 5-
fluorouricil chemotheraputic treatments. 









Gemcitabine 4 4 8 
breast Invasive 
Carcino a 




Gemcitabine 1 0 1 
cholangiocarci
noma 












Gemcitabine 1 2 3 
lung squamous 
cell carcinoma 








Gemcitabine 0 1 1 
sarcoma Gemcitabine 1 5 6 
skin cutaneous 
melanoma 
Gemcitabine 0 2 2 
testicular germ 
cell tumors 




Gemcitabine 0 1 1 




Florouricine 2 2 4 
esophageal 
carcinoma 












Florouricine 19 16 35 




 Independent predictive models were built for GEM and for 5-FU utilizing the 
gene expression and patient outcome data obtained from the TCGA database. Unlike our 
earlier models that were built using microarray gene-expression data [85], the gene-
expression values in the TCGA dataset are recorded as RNAseq profiles. Our model 
building and testing methods, however, remain essentially as previously described [85].  
In the TCGA database, patient responses to drugs are grouped into 4 categories: 
complete response, partial response, progressive disease and stable disease. Since the 
current configuration of our algorithms require a binary input with respect to drug 
response, we classified patients displaying either complete or partial response to the drug 
treatment as responders (R) and those displaying progressive or stable disease following 
treatment as non-responders (NR) (Table 3).  
The profiles of 75% of the patients (i.e., 69 patients for GEM; 45 patients for 5-
FU) were randomly selected to establish the learning datasets for model building and the 
remaining 25% (i.e., 23 patients for GEM; 15 patients for 5-FU) were employed as the 
test datasets for initial evaluation of the models.  
ML models built from large datasets typically contain uninformative features that 
can reduce predictive accuracy. For this reason, several feature selection methods have 
been developed to establish subsets of features with optimal predictive accuracy [67, 86] . 
In our studies, we employ a recursive feature elimination (RFE) method [85] to select for 
features (i.e., gene-expression patterns) that can optimally distinguish between predicted 




features of the model from the sorted feature list (Supplementary table 7). The subsequent 
SVM model is built on the remaining features and again, features with the lowest weights 
are removed. This process proceeds in a recursive manner until a minimal subset of 
features is identified that is essential to maintain optimal predictive accuracy.  Figure 22 
depicts the evolution of predictive accuracy using SVM-RFE feature selection for 
increased sensitivity to GEM and 5-FU. The minimum number of informative features 
associated with optimally predicted responsiveness to GEM was 81and for 5-FU was 31 
(Supplementary table 8).  
 
Figure 22 – Evolution of accuracy of predicted response to gemcitibine (A) and 5-
Fluorouricil (B) using SVM-RFE selection for gene probe classifiers. 
Employing a set of most informative features, the SVM-RFE models generate 
drug prediction scores for each patient. Scores greater than "0" indicate a predicted 
positive response to the drug while scores less than "0" are predictive of drug resistance. 
Figure 23 displays the distribution of prediction scores for the 92 patients treated with 
gemcitabine and the 60 patients treated with 5-FU (see also Supplementary table 9). 
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Patients observed to respond positively to the drug therapy are represented in the figures 
by blue dots and those observed not to respond to the therapy by red dots. The overall 
accuracies (gemcitabine 81.5%; 5-FU 84.1%), sensitivities (gemcitabine 75.7%; 5-FU 
88.6%), and specificities (gemcitabine 85.5; 5-FU 76.0%) of the two models were 
determined by leave-one-out cross validation (LOOCV) as previously described [85]. 
The high accuracy of our SVM-based models to predict individual patient responses to 
these two chemotherapeutic drugs is comparable to our previously reported accuracy 
(>80%) to predict the collective responses of 273 ovarian cancer patients to 7 
chemotherapeutic drugs [85]. 
 
Figure 23 – Individual and aggregate prediction of response to chemotherapeutic 
drugs. The SVM algorithms output binary classifications for gemcitabine and 5-
fluorouricil (red=drug sensitive; blue=drug resistant) established through a decision 
function that numerically separates tumors predicted to respond to the drug 









































































5.2.2 The response of individual ovarian cancer patients to standard-of-care therapies 
is predicted with high accuracy 
 The above studies generally support the potential of our SVM-RFE approach to 
accurately predict the drug responsiveness of individual cancer patients. To further assess 
the accuracy and evaluate the potential clinical usefulness of our approach, we conducted 
gene expression profiling of tumors collected from a randomly selected group of ovarian 
cancer patients and used SVM-RFE-based models to predict patient responsiveness to 
seven drugs often used in the treatment of ovarian cancer (carboplatin, cisplatin, 
paclitaxel, docetaxel, gemcitabine, doxorubicin, gefitinib).  
 Samples of primary tumors collected from 23 ovarian cancer patients (Table 
4) were snap frozen in liquid nitrogen within one minute of surgical removal and 
transferred to the lab for laser capture microdissection of cancer cells and 
subsequent microarray gene-expression analysis (Affymetrix, U133Plus 2.0 arrays) 
as previously described [87]. Nearly all (21/23) of the collected samples were serous 
papillary ovarian cancers with the remaining two classifieds as an adenocarcinoma 
and a malignant mesodermal mixed tumor (MMMT). The vast majority (19/23) of 
the samples were derived from patients with moderate to high-grade (Grade 2-3), 
late stage (Stage III/IV) disease. Four of the samples were derived from patients 








Table 4 – Clinical stage, grade and type of 23 ovarian cancer patients included in 
this study. 
Patient ID age at time of surgery 
histopathology of 
tumor stage grade 
229 58 serous papillary IIIc 3 
242 63 serous papillary IIIb 3 
272 83 adenocarcinoma IIIb 2/3 
286 52 serous papillary IIIc 2/3 
317 59 serous papillary Ic 3 
336 63 serous papillary Ic 3 
367 56 serous papillary II 3 
413 49 serous papillary IIb 3 
489 48 serous papillary IV 3 
528 66 serous papillary IIIc 3 
542 61 serous papillary IV 3 
545 74 MMMT IIIc 3 
588 71 serous papillary IIIc 2/3 
617 64 serous papillary IIIc 2/3 
620 62 serous papillary III/IV 3 
813 56 adenocarcinoma III 1/2 
992 73 serous papillary IIIc 3 
1012 75 serous papillary IIIc 3 
1122 65 serous papillary IIIc 3 
1129 65 serous papillary IIIc 3 
1145 41 serous papillary IIIc 3 
BJ1 40 serous papillary III 3 




 The majority of patients (17/23) were administered chemotherapy shortly after de-
bulking surgery with six patients receiving neo-adjuvant chemotherapeutic treatment 
prior to surgery. Most of the patients were treated with standard-of-care 
carboplatin/paclitaxel combination therapy (17/23).  One patient was treated with 
carboplatin and gemcitabine, one with carboplatin and docetaxel and one with 
carboplatin, cisplatin and paclitaxel combination therapies. Only two patients were 
treated with a single drug-one with topotecan and one with doxorubicin (Table 5,  
Supplementary table 10).   
Table 5 – Predicted and observed responses of 23 ovarian cancer patients treated 
with one or more of 7 chemotherapeutic drugs. 
 
 
Patient Drug OBSERVED RESPONSE 
PREDICTED PREDICTED PREDICTED PREDICTED PREDICTED PREDICTED PREDICTED PREDICTED 
Carboplatin Paclitaxel Cisplatin Gemcitabine Docetaxel Doxorubicin Gefitinib Topotecan 
229 Carbo&GEM R (TP) NR (FN) NR R R (TP) R NR R NR 
242 Carbo&Taxol R (TP) R (TP) NR (FN) NR NR R R R NR 
272 
Carbo&Taxol NR (FP) NR (TN) R (FP) NR R R NR NR NR 
286 
Carbo&Taxol NR (TN) NR (TN) NR (TN) NR NR NR R R NR 
317 
Carbo&Taxol R (TP) R (TP) R (TP) R R NR R NR NR 
336 
Carbo&Taxol R (TP) R (TP) R (TP) R R R NR NR NR 
367 
Carbo&Taxol R (TP) R (TP) R (TP) NR R NR NR NR NR 
413 
Carbo&Taxol R (TP) R (TP) R (TP) NR R R R NR NR 
489 
Carbo&Taxol R (TP) R (TP) R (TP) NR NR NR NR NR R 
526 
Carbo&Taxol R (TP) R (TP) R (TP) NR NR R NR NR NR 
542 
Carbo&Taxol R (TP) R (TP) R (TP) NR R NR NR NR NR 
545 
Carbo&Taxol NR (TN) NR (TN) NR (TN) NR R R NR NR R 
588 
Carbo&Taxol R (TP) R (TP) NR (FN) R R R NR NR R 
617 
Carbo&Taxol R (TP) R (TP) R (TP) NR R NR NR NR NR 
620 
Carbo&Taxol R (TP) R (TP) R (TP) NR R NR NR NR NR 
813 
Carbo/Cis/Taxol R (TP) NR (FN) R (TP) R (TP) NR NR NR NR NR 
992 
Topotecan NR(TN) R NR NR R NR NR NR NR (TN) 
1012 Carbo & 
doxetaxel NR (FP) NR (TN) NR R R R (FP) R NR NR 
1122 
Carbo & Taxol R (TP) NR (FN) R (TP) NR R NR NR NR NR 
1129 
Docorubicin R (TP) NR R R R NR R (TP) NR NR 
1145 
Carbo & Taxol NR (FP) R (FP) NR (TN) NR NR NR NR NR R 
BJ1 
Carbo & Taxol R (FN) NR (FN) NR (FN) R R NR NR NR NR 
BJ4 
Carbo&Taxol R (TP) NR (FN) R (TP) R R R R NR NR 
Totals: 





 The RNA expression profiles of significantly expressed genes were uploaded to 
our previously established SVM-algorithms 
(https://github.com/chuang95/KEA_DrugResponse) to generate drug prediction scores 
for each of seven chemotherapeutic drugs. We included all microarray probe sets for each 
gene in our analysis because, as previously demonstrated [85], the averaging of 
expression values over multiple probe sets can significantly reduce predictive accuracies. 
As described above, the predictive algorithms generate scores for each drug.  Scores 
greater than "0" indicate a predicted positive response to the drug while scores less than 
"0" are predictive of drug resistance (e.g., Fig. 24A, B Fig. 35).  
 The majority of the 23 ovarian cancer patients analyzed were predicted to respond 
favorably to gemcitabine (17/23), carboplatin (13/23) and paclitaxel (13/23) (Table 5, 
Supplementary table 10) with less than half to cisplatin (9/23) and docetaxel (10/23).  
Less than third of the 23 patients were predicted to respond to doxorubicin (7/23), 
topotecan (4/23) or gefitinib (3/23). These predicted efficacies are generally consistent 
with our earlier group predictions of 273 OC patients with the exception of gemcitabine, 
which in our previous study, was ranked immediately behind carboplatin in predicted 
efficacy. This inconsistency may be attributable to sampling error due to the relatively 
few patients employed in the current study. 
 To evaluate the accuracy of our predictions, patient responses to administered 
chemotherapies were monitored by measurement of CA-125 values prior and subsequent 
to treatment according to standard criteria [88]. Patients were considered to be responsive 
to treatments if their respective CA-125 values dropped below normal values (<35) 





Figure 24 – Comparison of the predicted and observed responses of two ovarian 
cancer patients to carboplatin and paclitaxel therapies. The predicted response 
scores of each patient (red line) are plotted over the distribution of previously the 
predicted scores of 273 ovarian cancer patients [6]. Patient 286 (A) is predicted to 
not to respond to either drug (negative scores) while patient 336 (B) is predicted to 
respond to both drugs according to standard criteria [13]. Patients are considered to 
be responsive to treatments if their respective CA-125 values dropped below normal 
values (<35) within 60 days of the start of chemotherapeutic treatment (red dashed 
line indicates day of surgery). Patient 286 (C) is a non-responder while patient 336 
(D) is a responder. 
 Our algorithms predict responses to individual drugs and in those few cases where 
patients were treated with a single drug, evaluation of the model's predictive accuracy is 



































































































































standard-of-care chemotherapy for ovarian cancer patients typically involves treatment 
with multiple drugs, most commonly, carboplatin and paclitaxel. In those cases where 
patients were observed to positively respond to the combination therapies, the prediction 
was scored as "true positive" (TP) if the patient is predicted to respond to at least one of 
the administered drugs (e.g., patients 317 and 588). Conversely, in cases where patients 
were observed to not respond to the combination therapy, the prediction was scored as 
"false positive" (FP) if the patient was predicted to respond to at least one of the drugs 
(e.g., patients 272 and 1012, Table 5, Supplementary table 10).  Instances where the 
patient is both predicted and observed not to respond to the combination therapy are 
scored as "true negative" (TN) (e.g., patients 317 and 545, Table 5, Supplementary table 
10) while cases where the patient responded to the combination therapy but is predicted 
not to respond to any of the administered drugs was scored as "false negative" (FN) (e.g., 
patient BJ1, Table 5, Supplementary table 10).  
 Based on these criteria, the computational predictions resulted in 16 TP, 3 TN, 3 
FP and 2 FN.  This equates to a positive predictive value (PPV) of 84.2% (sensitivity 
94.1%), a negative predictive value (NPV) was 75% (specificity of 50%) equating to an 
overall accuracy of 83.6%. The low specificity may, in part, be due to sampling error 
since only six patients were observed to be non-responders in this study group.  
 One possible clinically useful application of our models is depicted in Figure 24. 
As shown (see also Figure 35), the predictive scores of an individual patient can be 
mapped across the distributed scores of all previously profiled patients providing 
information on those drugs most likely to be effective as second line treatments for an 
individual patient. Patient 545 was both predicted and observed (Table 5, Supplementary 
table 10) not to respond to carboplatin/paclitaxel treatment. An estimated 20-30% of all 




fail to respond to treatment [75] leaving physicians with the decision as to what to try 
next. ML-based models with validated high positive predictive values, such as reported 
here, and may provide physicians with a useful alternative to the traditional trial-and-
error strategies. For example, based on the predicted responses of patient 545 to the 






Figure 25 – Algorithms with high positive predictive value (PPV) may be of 
particular clinical benefit in the selection of alternative second-line chemotherapies. 
Patient 545 was predicted (and observed, see Table 5) not to respond to standard-of-
care carboplatin/paxitaxel therapy. Of possible second-line therapies, gemcitabine is 




































































































5.3 Discussion  
Cancer is a complex disease. The fact that there are a multitude of possible 
molecular paths to developing even the same type of cancer explains, in large measure, 
why the response to any given chemotherapeutic drug can be highly variable across 
patients [89]. Our increasing ability to accurately profile individual patient tumors on the 
molecular level is widely viewed as a promising resolution to this problem. Indeed, a 
major goal of modern cancer medicine is the ability to accurately predict optimal drug 
therapies based upon the personalized molecular profiles of individual patient tumors.  
Accurate predictions in cancer biology, as in all areas of science, can be based upon 
established cause-and-effect relationships or upon highly significant correlations detected 
in large sets of relevant data. While we are well on our way to the day when we may fully 
understand the molecular causes of all cancers and treat them accordingly, we are not 
there yet. One promising interim solution is the application of prediction algorithms 
derived from ML-detected correlations between the molecular profiles of large numbers 
of cancers and associated responses to variety of therapeutic drugs [90]. 
We recently reported on the use of our open access SVM-based algorithms to 
accurately (>80%) predict the collective response of 273 ovarian cancer patients to seven 
commonly prescribed chemotherapeutic drugs [85]. In this study, we were interested in 
evaluating the performance of our approach to predict individual patient responses to 
drugs based on gene expression profiles of each individual tumor. Employing gene 




database, we were able to predict the response of individual patients treated with either 
gemcitabine or 5-FU with >81% accuracy.  In a second study, the response of individual 
ovarian cancer patients to seven commonly prescribed chemotherapeutic drugs, based on 
microarray gene expression profiles of each patient's tumor, was predicted with an overall 
accuracy of 83% and a PPV of 84%.  The high PPV of our algorithms across multiple 
drugs suggests a potential clinical utility of our approach to identify promising second-
line treatments for patients failing standard-of-care first-line therapies.  
It should be noted that although our models have, thus far, focused on the predicted 
response of cancer patients to current standard-of-care drug therapies for which sufficient 
datasets are available, the approach is equally as well applicable to emerging immuno- 
and other targeted gene therapies where patient responses are also known to be variable 






CHAPTER 6. FUTURE WORK AND CONCLUSION 
 Overall this work in totality reflects our deep seeded belief that algorithms and 
heuristics that advance precision medicine should be open source to allow the maximum 
benefit for humanity. Through two major types of analysis my present work has moved 
the needle forward in terms of genomic comparisons of sequences useful for comparative 
genomics (i.e. Boolean based genomic topology) as well as key formatting of data types 
to allow for automated and rapid analysis that scales with arbitrarily large datasets.  
 This technique enables the comparison of highly divergent genomic sequences 
and we utilize these heuristics to perform hPCA clustering of bacterial and viral 
sequences (Fig. 26A). As well as clustering based on pairwise distance of Boolean 
analysis shown in Figure 26B. In addition to finding a number of known relationships 
between bacteria and viruses, we also found evidence of previously cryptic relationships 
between these bacterial and viral genomes (Appendix A1, Table 6, 7). These 
relationships highly suggestive of shared genomic content through horizontal gene 
transfer, and provide a new perspective to examine these putative new relationships 
between of bacteria and viruses. We prepared a k-merized data set of 2569 bacteria and 
1754 virus sequences for further study. Future work will allow clustering of arbitrarily 
large sets of genomes across diverse phyla, something that is not possible with 
conventional alignment based heuristics. We also see the possibility of capturing all 
deposited sequences for a given outbreak and plot newly sequenced isolates in the 






Figure 26 – Scaled Linear algebra and Boolean analysis. A) Orthogonal 
transformation of the matrices from 2569 number bacteria (green) and 1754 
number viruses (in red). B) Hierarchical tree based on pairwise distance of Boolean 
analysis. 
 After achieving scaled clustering of microbial genomic data (as seen above), we 
went ahead and extended our drug response prediction algorithm to analyze a larger set of 
cancer drugs. In Chapter IV and V, we analyzed 7 FDA proved drugs for ovarian cancer 
patients. Since we didn't want to limit our algorithm only on prediction drug response for 
ovarian cancer patients, we selected 95 FDA-approved drugs that were screened with the 
NCI-60 cell lines and that have GI-50/IC-50 data. We built a model for each drug, and 
initially test these models on ovarian cancer patient clinical trials (GSE20565, 
GSE18521, GSE30161). As shown in Figure 27, the density plot of drug response for two 
example drugs, Thiotepa and Vorinostat, are similar to the predicted efficacy result for 
Carboplatin. Based on these results, we can start to predict which drug could be effective 
for treating ovarian cancer patients. Looking into the literature and without our prior 
knowledge, it turns out that both Thiotepa and Vorinostat have recently been utilized in 
clinical trials for ovarian cancer [92, 93]. Looking at global scale response off of our 
predication model could be a way in which to help prioritize specific drug candidates 






prediction models improve. Next steps include being able to carry our prospective 
clinical trials to match drugs with patient profiles.  
 
Figure 27 – Density plot of aggregate prediction scores for 3 GEO data sets of 273 
ovarian cancer patients and the predicted group response rate for drug A) Thiotepa 
and B) Vorinostat comaparing to drug Carboplatin. 
  In addition to the work above we are developing the project's website to allow 
interested parties to view and download the source code, as well as obtain additional 
information about the algorithmic basis of our current version 
(http://vannberg.biology.gatech.edu/data/DrugResponse/). We envision that this work, 
alongside other academic and commercial groups, forms the basis of a broad reaching 
truly open source drug sensitivity algorithm development challenge moving forward. For 
this, developers can access large sets of pre-formatted data and the competition will be 
set up with an initial working pipeline for computer engineers to be able to start and to 
then subsequently optimize to continue to improve and optimize the performance of 
prediction. To date our group has achieved data wrangling of nearly all of the available 
NCBI GEO datasets into one matrix for a given array. For example, we have processed 






























































separate arrays processed into a single matrix to allow for direct normalization to the 
analysis set of interest (in this case the NCI-60 set). Although we have utilized MAS5 
normalization for the work outlined in this thesis future work will utilize another 
normalization technique more precisely suited for probe level analysis. Also, instead of 
gene level RNA-seq data, a model built on exome level RNA-seq data could improve the 
performance of drug response prediction. These approaches may increase the accuracy, 
sensitivity and specificity of our analysis. By combining all of this data together, we 
provide a matrix format that is inherently easy to access and manipulate. By doing so we 
can compare any new cancer sample with all others to allow for algorithmic prediction of 
not only drug response, but also putative tissue of origin, clonal heterogeneity, stromal 
cell contamination, immune cell infiltration, and other key metrics that will be useful in 
future therapeutic decision making. By making this resource open and easy to use we can 
envision how cancer care will progress and how these advancements can be added into 
future electronic health care record (EHR) fields. Our lab has also attempted to automate 
plots for the assessment of drug response (i.e., CA125 plots) and more work will need to 
be done on this to ultimately automate and integrate all data which can help to determine 
drug response into a cohesive analysis. We invasion that neural networks will serve to 
benefit key modules of our work flow, and might useful to improve the performance of 
current algorithm. By minutely understanding the exact tumor response for each drug and 
dose we can continue the virtuous circle of continued training of the drug response 
algorithms to further increase accuracy. All of these developments add transparency and 
allow developers to learn from each other in real time and to iterate to improve these 
algorithms and we look forward to opening up a drug sensitivity prediction challenge in 
the near future to allow academic and commercial researchers locally and abroad to 




 Through this work I’ve been able to produce open source scripts that involve both 
supervised as well as unsupervised machine learning, and my work serves as an initial 
template to power collaborative efforts in topics such as drug response for cancer drugs, 
outbreak discovery for infectious diseases, and other areas not covered in this dissertation 
including variant calling for drug resistance and other important topics.  
 Additional optimizations and data scaling remain to be carried out, but this 
dissertation presents a defined answer to the numerous studies in this space that shared 
very little true open source code when assessing drug response. I believe that clarity of 
thought is reflected in the elegance of a given algorithm and data format, and throughout 
this dissertation implementation of the kmatrix format, alongside the Boolean XOR 
function form what must be the absolute most succinct and elegant approach to this given 
problem. In terms of machine learning those that are at the forefront of the field have 
suggested a similar philosophical thought, and I hope that through this dissertation others 
will also search out this type of philosophical aim to produce algorithms that are not only 






A.1  Relationships between bacteria and viruses 
 This technique enables the comparison of highly divergent genomic sequences 
and we utilize these heuristics to perform clustering of bacterial and viral sequences (Fig 
26, Table 6, 7). From genomic topology analysis, we find examples that make sense in 
terms of likely horizontal gene transfer such as a close link between Sulfolobus virus 
STSV1 and Sulfolobus islandicus M; Sulfolobus virus STSV1 and Sulfolobus solfataricus; 
Sulfolobus virus STSV1 and Sulfolobus acidocaldarius; Sulfolobus virus STSV1 and 
Sulfolobus tokodaii [94]; Salmonella phage ST64B and Escherichia coli ED1a [95]; 
Klebsiella phage phiKO2 and Escherichia coli O26 [96]. However, this analysis also 
revealed several unexpected relationships between Klebsiella phage phiKO2 and 
Enterobacter cloacae EcWSU1; Enterobacteria phage N15 and Pectobacterium 
atrosepticum SCRI1043, among others.  
 We demonstrate that our approach can analyze an ancient genome such as 
Acidianus bottle shaped virus, which infect archaea [97], in the context of other viruses. 
By using grep function, we output pairwise relationship between Acidianus bottle shaped 
virus and all other species in our database, then we sorted by the hPCA distance. We find 
out close virus spices have stronger relationship than other random picked and bacteria 
(Fig. 28). Also, we can to study the relationship between this virus and other bacteria. So, 
we show a circus plot of several bacteria, which have low hPCA distance with the virus, 




Methylobacterium family are far away from our virus, because they are less related than 
the Vulcanisaeta moutnovskia [98]  to the virus, and it is an Archaea, which might be 
infected by Acidianus bottle shaped virus. Besides, Caldivirga maquilingensis, 
Ignisphaera aggregans, Vulcanisaeta distribute, Desulfurococcus fermentans, are all 
Archaea. This suggests that there is relationship between virus and infected bacteria on 
genome perspective. For another example, we can study on an unclassified sequence, and 
suggest classification. We pick an unclassified virus, Pyrococcus abyssi virus 1. By using 
grep function, we output relationship between this virus and all other species in our 
database. After sorting the output by hPCA distance, we study the top 12 species (log-
transformed hPCA distance higher than 2.5) and their lineage (Table 6). From the table, 
we can see that most of these known species are belong to Viruses; dsDNA viruses, no 
RNA stage; Caudovirales family. So, we can positively suggest that Pyrococcus abyssi 





Figure 28 – Circus plot of five Acidianus family virus, one random herpesvirus and 
one random Starkeya.novella bacteria. The pairwise relationship are present by 
10/(hPCA distance), so the thicker the connect line is, the closer they are.  
Combining our Boolean Analysis algorithm with hPCA result can be more 
advanced to study certain species. For example, we pick another unclassified virus, 
Sulfolobus tengchongensis spindle-shaped virus 1 (STSV1). We output the pairwise 
relationship between STSV1 and other species in our database and we sort the output by 




species are belonging to Sulfolobus islandicus family (Table 7). It’s positive to believe 
that STSV1 is a virus that infects Sulfolobus islandicus family. 
Table 6 – Pairwise relationship between Pyrococcus abyssi virus 1 and top 12 close 




Xanthomonas.phage.OP2 Pyrococcus.abyssi.virus.1 0.00113 2.946938 Viruses; dsDNA viruses, no RNA 
stage; Caudovirales; Myoviridae. 
Pyrobaculum.spherical.virus Pyrococcus.abyssi.virus.1 0.001583 2.800532 Viruses; dsDNA viruses, no RNA 
stage; Globuloviridae; Globulovirus. 
Morganella.phage.MmP1 Pyrococcus.abyssi.virus.1 0.002079 2.682144 Viruses; dsDNA viruses, no RNA 
stage; Caudovirales; Podoviridae; 
Autographivirinae; T7likevirus. Hyperthermophilic.Archaeal.Virus.1 Pyrococcus.abyssi.virus.1 0.002292 2.639807 Viruses; dsDNA viruses, no RNA 
stage; unclassified dsDNA viruses. 
Phormidium.phage.Pf.WMP3 Pyrococcus.abyssi.virus.1 0.00238 2.623421 Viruses; dsDNA viruses, no RNA 
stage; Caudovirales; Podoviridae. 
Burkholderia.phage.KS9 Pyrococcus.abyssi.virus.1 0.002698 2.569013 Viruses; dsDNA viruses, no RNA 
stage; Caudovirales; Siphoviridae; 
Lambdalikevirus; unclassified 
Lambda-like viruses. 
Yersinia.pestis.phage.phiA1122 Pyrococcus.abyssi.virus.1 0.002732 2.563507 Viruses; dsDNA viruses, no RNA 
stage; Caudovirales; Podoviridae; 
Autographivirinae; T7likevirus. Enterobacteria.phage.SSL.2009a Pyrococcus.abyssi.virus.1 0.002814 2.550622 Viruses; dsDNA viruses, no RNA 
stage; Caudovirales; Siphoviridae 
Enterobacteria.phage.T7 Pyrococcus.abyssi.virus.1 0.00284 2.546674 Viruses; dsDNA viruses, no RNA 
stage; Caudovirales; Siphoviridae 
Burkholderia.phage.phiE255. Pyrococcus.abyssi.virus.1 0.002842 2.546378 Viruses; dsDNA viruses, no RNA 
stage; Caudovirales; Siphoviridae; 
Lambdalikevirus; unclassified 
Lambda-like viruses. 
Enterobacteria.phage.13a Pyrococcus.abyssi.virus.1 0.002894 2.538576 Viruses; dsDNA viruses, no RNA 
stage; Caudovirales; Siphoviridae 
Burkholderia.phage.Bcep176 Pyrococcus.abyssi.virus.1 0.003103 2.508226 Viruses; dsDNA viruses, no RNA 








Table 7 – Pairwise relationship between Sulfolobus tengchongensis spindle-shaped 
virus 1 and top 10 close Bacteria sorted by the average of log transformed hPCA 
and Boolean Analysis distance. 
S1 S2 hPCA ∆𝜞𝒌 Average 
Sulfolobus.virus.STSV1 Sulfolobus.islandicus.LAL14.1 3.3619 0.1783 1.7701 
Sulfolobus.virus.STSV1 Sulfolobus.islandicus.HVE10.4 3.3430 0.1728 1.7579 
Sulfolobus.virus.STSV1 Sulfolobus.islandicus.M.14.25 3.2903 0.1733 1.7318 
Sulfolobus.virus.STSV1 Sulfolobus.islandicus.Y.G.57.14 3.2702 0.1714 1.7208 
Sulfolobus.virus.STSV1 Sulfolobus.islandicus.Y.N.15.51 3.2490 0.1709 1.7100 
Sulfolobus.virus.STSV1 Sulfolobus.islandicus.REY15A 3.2314 0.1786 1.7050 
Sulfolobus.virus.STSV1 Sulfolobus.islandicus.L.S.2.15 3.1989 0.1688 1.6839 
Sulfolobus.virus.STSV1 Sulfolobus.islandicus.L.D.8.5 3.1872 0.1679 1.6775 
Sulfolobus.virus.STSV1 Sulfolobus.islandicus.M.16.27 3.1653 0.1718 1.6686 















A.2  Feature selection algorithms comparison 
Take drug Carboplatin as example, we compare our approach to two common used 
feature selection techniques, PCA and sequential forward selection. 
 
Figure 29 – Comparing LOOCV evaluation of three feature selection 
approaches. The statistical report (accuracy, sensitivity and specificity) in the figure 













































































































































































ACC = 84.1% 
SEN = 72.2% 

























ACC = 60.0% 
SEN = 50.0% 

























ACC = 71.4% 
SEN = 75.0% 
SPE = 69.6% 
SVM-RFE PCA SFS 




A.3  Drug response prediction for all 6 drugs 
 
Figure 30 – Labels of response to each drug of NCI-60 cell lines are determined by 
IC50 value. Here we show negative log transformed IC50 value of NCI-60 cell lines 
for each drug. The higher the negative log transformed 50 value, the more sensitive 
response cell lines are. Data between mean+0.5*std and mean-0.5*std are removed 

























































































































































































due to undetermined of response. Data points beyond mean+0.5*std are labeled as 
1(response) and data points below mean-0.5*std are labeled as 0(not response). 
 
Figure 31 – RFE performance for each drug. We plot accuracy, sensitivity, and 
specificity for each step of RFE.  
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Figure 32 – Leave-one-out cross-validation for each model. We plot GI-50 of each 
data points (y axis) against its prediction score (x axis).  
 







































































































































































































Figure 33 – We first built a model using 18 cell lines from lung cancer and 
melanoma (i.e. 2 cancer types) and another model using 18 cell lines from brain, 
breast, lung, leukemia, renal, colon, ovarian, prostate and melanoma cancer cells 
(i.e. 9 cancer types). We LOOCVs for two models and show the first model performs 
better. 
 
Figure 34 – We select one gene (MIR612_///_NEAT1), which has 7 probe sets in our 
NCI-60 gene expression data. This box plot shows the expression variation for 
probes in one gene. The red dot line shows the average (11.3) of all probes to gene 
level. 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 35 – The predicted response scores of each of the 23 ovarian cancer patients 
analyzed in this study (red lines) are plotted over the distribution of previously the 







































































































































































































































































































































































Figure 36 – Patients are considered to be responsive to treatments if their respective 
CA-125 values dropped below normal values (<35) within 60 days of the start of 
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